1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
Commission file number: 0-19311
IDEC PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
California 33-0112644
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
11011 Torreyana Road, San Diego, CA 92121
(Address of principal executive offices) (Zip code)
(619) 550-8500
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes _X_ No ___
As of October 31, 1996, the Registrant had 18,016,354 shares of its common
stock, no par value issued and outstanding.
2
IDEC PHARMACEUTICALS CORPORATION
FORM 10-Q -- QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1996
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets -- September 30, 1996 and December 31, 1995 .......... 1
Condensed Consolidated Statements of Operations -- Three months ended September 30, 1996 and
1995 and nine months ended September 30, 1996 and 1995 .................................. 2
Condensed Consolidated Statements of Cash Flows -- Nine months ended September 30, 1996 and
1995 .................................................................................... 3
Notes to Condensed Consolidated Financial Statements ....................................... 4
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ...... 5
PART II. OTHER INFORMATION
Item 1. Legal Proceedings .......................................................................... 12
Item 2. Changes in Securities ...................................................................... 12
Item 3. Defaults upon Senior Securities ............................................................ 12
Item 4. Submission of Matters to a Vote of Shareholders ............................................ 12
Item 5. Other Information .......................................................................... 12
Item 6. Exhibits and Reports on Form 8-K ........................................................... 12
3
PART I -- FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS.
IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
September 30, December 31,
1996 1995
--------- --------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 53,105 $ 18,828
Securities available-for-sale 22,971 5,182
Current portion of note receivable 761 640
Contract research revenue receivables 2,850 1,455
Inventories 1,729 --
Prepaid expenses and other current assets 2,944 1,333
--------- --------
Total current assets 84,360 27,438
Property and equipment, net 17,921 17,955
Restricted marketable security -- 750
Note receivable, less current portion 672 1,249
Deposits and other assets 341 234
--------- --------
$ 103,294 $ 47,626
========= ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of notes payable $ 3,656 $ 3,248
Trade payable - clinical materials -- 238
Accounts payable 1,291 970
Accrued expenses 4,105 4,280
--------- --------
Total current liabilities 9,052 8,736
Notes payable, less current portion 5,386 6,598
Other long-term liabilities 2,402 1,123
Shareholders' equity (Note 2):
Convertible preferred stock, no par value 26,586 14,086
Common stock, no par value 142,426 93,554
Additional paid-in capital 2,449 2,379
Unrealized gains on securities available-for-sale -- 10
Accumulated deficit (85,007) (78,860)
--------- --------
Total shareholders' equity 86,454 31,169
--------- --------
$ 103,294 $ 47,626
========= ========
See accompanying notes to condensed consolidated financial statements.
1
4
IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three months Nine months
ended September 30, ended September 30,
------------------------ ------------------------
1996 1995 1996 1995
-------- -------- -------- --------
Revenues:
Sales $ -- $ -- $ 1,505 $ --
Contract research revenues 2,902 1,375 8,902 6,924
License fees -- 1,000 9,500 6,000
-------- -------- -------- --------
2,902 2,375 19,907 12,924
Operating expenses:
Cost of sales -- -- 1,384 --
Research and development 6,292 5,347 19,011 16,280
General and administrative 1,844 1,672 5,305 4,677
Acquired technology rights -- -- -- 11,437
-------- -------- -------- --------
8,136 7,019 25,700 32,394
-------- -------- -------- --------
Loss from operations (5,234) (4,644) (5,793) (19,470)
Interest income (expense), net 730 (279) (354) (484)
-------- -------- -------- --------
Net loss $ (4,504) $ (4,923) $ (6,147) $(19,954)
======== ======== ======== ========
Net loss per common share $ (0.26) $ (0.32) $ (0.38) $ (1.37)
======== ======== ======== ========
Shares used in computing net loss
per common share 17,528 14,869 16,127 14,550
======== ======== ======== ========
See accompanying notes to condensed consolidated financial statements.
2
5
IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
Nine months ended
September 30,
------------------------
1996 1995
-------- --------
Cash flows from operating activities:
Net cash used in operating activities $ (5,926) $ (7,967)
-------- --------
Cash flows from investing activities:
Purchase of property and equipment (1,993) (848)
Purchase of securities available-for-sale (31,324) (6,888)
Sales and maturities of securities available-for-sale 14,274 2,492
-------- --------
Net cash used in investing activities (19,043) (5,244)
-------- --------
Cash flows from financing activities:
Proceeds from notes payable 1,790 2,785
Payments on notes payable (2,557) (3,321)
Net proceeds from issuance of common stock 47,513 210
Proceeds from issuance of preferred stock 12,500 7,149
-------- --------
Net cash provided by financing activities 59,246 6,823
-------- --------
Net increase (decrease) in cash and cash equivalents 34,277 (6,388)
Cash and cash equivalents, beginning of period 18,828 13,691
-------- --------
Cash and cash equivalents, end of period $ 53,105 $ 7,303
======== ========
See accompanying notes to condensed consolidated financial statements.
3
6
IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The information at September 30, 1996, and for the three and nine months ended
September 30, 1996 and 1995, is unaudited. In the opinion of management, these
financial statements include all adjustments, consisting of normal recurring
adjustments, necessary for a fair presentation of results for the interim
periods presented. Interim results are not necessarily indicative of results for
a full year. These financial statements should be read in conjunction with IDEC
Pharmaceuticals Corporation's Annual Report on Form 10-K for the year ended
December 31, 1995, which was filed with the United States Securities and
Exchange Commission on April 1, 1996.
Inventories
Inventories are stated at the lower of cost or market. Cost is determined in a
manner which approximates the first-in, first-out (FIFO) method.
New Accounting Standards
Effective January 1, 1996, the Company adopted Financial Accounting Standards
Board Statement No. 123, "Accounting for Stock-Based Compensation" ("Statement
123"). Statement 123 allows companies to expand the use of fair value
accounting for stock compensation plans or requires companies that elect to
retain the current approach for recognizing stock-based compensation expense to
make annual pro forma disclosures of the Company's operating results as if they
had adopted the fair value method. Management of the Company has retained the
current approach for recognizing stock-based compensation which did not have a
financial effect on the Company's consolidated financial statements and will
report the annual pro forma disclosures in the notes to the fiscal 1996
consolidated financial statements.
Effective January 1, 1996, the Company adopted Financial Accounting Standards
Board Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and
for Long-Lived Assets to be Disposed Of" ("Statement 121"). Statement 121
requires impairment of losses to be recorded on long-lived assets used in
operations when indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets are less than the assets'
carrying amount. The adoption of Statement 121 did not have a material effect on
the Company's consolidated financial statements for the three and nine months
ended September 30, 1996.
NOTE 2. SHAREHOLDERS' EQUITY
Common Stock
In June 1996, the Company completed a public offering of 2,070,000 shares of its
common stock resulting in net proceeds of approximately $46,300,000.
Convertible Preferred Stock
The Company issued 23,000 shares of its Series A-3 Nonvoting Convertible
Preferred Stock ("Series A-3 Preferred Stock") in March 1996, and 100,000 shares
of its Series A-6 Nonvoting Convertible Preferred Stock ("Series A-6 Preferred
Stock") in May 1996, to Genentech, Inc. pursuant to the terms of a preferred
stock purchase agreement. The preferred stock purchase agreement was entered
into concurrently with a collaboration agreement in March 1995. The Series A-3
Preferred Stock and Series A-6 Preferred Stock are recorded on the balance sheet
at their liquidation preference per share of $217 and $75, respectively. Each
share of Series A-3 Preferred Stock is convertible at any time into ten shares
of common stock. Each share of Series A-6 Preferred Stock is convertible into
the number of shares of common stock equal to 75 divided by the average closing
price of the Company's common stock as reported by the Nasdaq National Market
for the 20 trading days following the earlier of (i) the FDA approval date for
IDEC-C2B8 or (ii) September 16, 2000.
4
7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
Since its inception, IDEC Pharmaceuticals Corporation (the "Company") has been
primarily engaged in the research and development of products for the long-term
management of immune system cancers and autoimmune and inflammatory diseases. To
date, the Company has not received any revenues from the commercial sale of its
products. The Company has funded its operations primarily through the sale of
equity securities as well as through contract research and license fee revenues
received in connection with collaborative arrangements entered into with the
Company's strategic partners. For the nine months ended September 30, 1996 and
the year ended December 31, 1995, the Company recognized contract research and
license fee revenues of $18.4 million and $23.6 million, respectively.
The Company has incurred increasing annual operating expenses and, as the
Company moves closer to product commercialization, it expects such trends to
continue. The Company has incurred annual operating losses since its inception
in 1985, and anticipates that such operating losses will continue for at least
the next one to two years. As of September 30, 1996, the Company had an
accumulated deficit of $85.0 million.
RESULTS OF OPERATIONS
Contract research revenues for the three and nine months ended September 30,
1996 totaled $2.9 million and $8.9 million, respectively, compared to $1.4
million and $6.9 million for the comparable periods in 1995. The increase in
contract research revenues for the three and nine months ended September 30,
1996 is due primarily to revenue from a new collaboration entered into with
Eisai Co., Ltd. in December 1995, partially offset by decreased revenues from
SmithKline Beecham, p.l.c. ("SmithKline Beecham") as a result of the planned
transfer of clinical development of IDEC-CE9.1 to SmithKline Beecham in late
1995.
License fees for the nine months ended September 30, 1996 totaled $9.5 million
compared to $6.0 million for the comparable period in 1995. The increase in the
license fees is due primarily to $4.5 million received for the license to Chugai
Pharmaceutical Co., Ltd. of the Company's proprietary gene expression technology
for the manufacture of recombinant proteins.
Sales and costs of sales for the nine months ended September 30, 1996 were a
result of the Company completing a contract manufacturing arrangement during the
second quarter of 1996.
Research and development expenses equaled $6.3 million and $5.3 million for the
third quarters of 1996 and 1995, respectively, and $19.0 million and $16.3
million for the nine months ended September 30, 1996 and 1995, respectively. The
increase in research and development expenses for the three months ended
September 30, 1996, is primarily due to increased personnel costs related to the
completion of the Phase III trial, preparation of the Biologics License
Application and the preparation for building of commercial inventory of the
Company's lead product candidate, IDEC-C2B8. The increase in research and
development expenses for the nine months ended September 30, 1996 is primarily
due to a $1.3 million expense for access to certain patent rights related to
IDEC-C2B8, increased personnel costs related to the completion of the Phase III
trial, preparation of the Biologics License Application and the preparation for
building of commercial inventory of the Company's lead product candidate,
IDEC-C2B8. The Company expects to continue incurring substantial additional
research and development costs in the future, due to expansion of research and
development programs; patent and regulatory related costs; preclinical and
clinical testing of the Company's various products under development; production
scale-up and manufacturing of products used in clinical trials; and
pre-commercialization-related manufacturing costs.
General and administrative expenses were $1.8 million and $1.7 million for the
third quarters of 1996 and 1995, respectively, and $5.3 million and $4.7 million
for the nine months ended September 30, 1996 and 1995, respectively. General and
administrative expenses for the nine months ended September 30, 1996, increased
due to higher personnel costs to support expanded manufacturing operations,
completion of the Phase III trial and preparation of the Biologics License
Application for IDEC-C2B8. General and administrative costs necessary to support
expanded manufacturing operations, expanded product development efforts and the
creation of a marketing and sales organization are expected to continue to
increase in the foreseeable future.
5
8
Beginning in 1988, the Company obtained funds from ML/MS Associates, L.P.
("ML/MS") for the development of the Company's lymphoma products. In connection
with such funding, ML/MS obtained rights in such products. In March 1995, the
Company repurchased such rights by the issuance of 1.0 million shares of its
common stock and 69,375 shares of 10% Series B Nonvoting Cumulative Convertible
Preferred Stock to ML/MS. In March 1995, the Company recorded a noncash charge
of $11.4 million, representing the purchase of the acquired technology rights.
Net interest income totaled $0.7 million for the three months ended September
30, 1996 compared to net interest expense of $0.3 million for the three months
ended September 30, 1995. Net interest expense totaled $0.3 million for the nine
months ended September 30, 1996 compared to $0.5 million for the comparable
period in 1995. Net interest income was generated for the three months ended
September 30, 1996 from the increase in cash, cash equivalents and securities
available-for-sale resulting from the completion of a public offering of 2.1
million shares in June 1996.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations and capital expenditures since inception
principally through the sale of equity securities, license fees, contract
research revenues, lease financing transactions and interest income. The Company
expects to finance its current and planned operating requirements principally
through cash on hand and with funds from existing collaborative agreements and
contracts which the Company believes will be sufficient to meet its near-term
operating requirements. Existing agreements and contracts, however, could be
canceled by the contracting parties. In addition, the Company may pursue
additional capital through a combination of new collaborative agreements,
strategic alliances, equity and debt financings. However, no assurance can be
provided that additional capital will be obtained through these sources on
favorable terms or at all. Should the Company not enter into any such
arrangements, the Company anticipates its cash, cash equivalents and securities
available-for-sale, together with the existing agreements and contracts, will be
sufficient to finance the Company's currently anticipated needs for operating
and capital expenditures through early commercialization of its first product.
If adequate funds are not available from additional sources of financing, the
Company's business could be adversely affected.
The Company's working capital and capital requirements will depend upon numerous
factors, including the progress of the Company's preclinical and clinical
testing; manufacturing; research and development programs; timing and cost of
obtaining regulatory approvals; levels of resources that the Company devotes to
the development of manufacturing and marketing capabilities; technological
advances; status of competitors; and the ability of the Company to establish
collaborative arrangements with other organizations.
Until required for operations, the Company's policy under established guidelines
is to keep its cash reserves in bank deposits, certificates of deposit,
commercial paper, corporate notes, United States government instruments and
other readily marketable debt instruments, all of which are investment-grade
quality.
At September 30, 1996, the Company had $76.1 million in cash, cash equivalents
and securities available-for-sale compared to cash, cash equivalents and
securities available-for-sale of $24.0 million at December 31, 1995. Sources of
cash, cash equivalents and securities available-for-sale for the nine months
ended September 30, 1996 include $12.5 million from the issuance of convertible
preferred stock, $47.5 million from the issuance of common stock (including
approximately $1.2 million from the exercise of stock options and from common
stock issued under an employee stock purchase plan) and $1.8 million from
funding under an existing lease line. Uses of cash, cash equivalents and
securities available-for-sale during the nine months ended September 30, 1996
include $5.9 million used in operations, $2.0 million used to purchase capital
equipment and $2.6 million used to pay notes payable.
In June 1996, the Company completed a public offering of 2,070,000 shares of its
common stock resulting in net proceeds of approximately $46.3 million. In May
1996, the Company issued 100,000 shares of its Series A-6 Convertible Preferred
Stock and in March 1996, the Company issued 23,000 shares of its Series A-3
Convertible Preferred Stock pursuant to terms of a preferred stock purchase
agreement with Genentech, Inc. ("Genentech") resulting in proceeds of $12.5
million.
In August 1995, the Company completed funding under a $10.0 million lease
financing agreement to finance both equipment and facility improvements. Terms
of the financing agreement require final principal payments of $1.1 million and
$0.4 million in July 1998 and January 1999, respectively.
6
9
This quarterly report contains predictions, estimates and other forward-looking
statements that involve a number of risks and uncertainties. While this outlook
represents management's current judgment on the future direction of the
business, such risks and uncertainties could cause actual results to differ
materially from any future performance suggested above. The Company undertakes
no obligation to release publicly the results of any revisions to these
forward-looking statements to reflect events or circumstances arising after the
date hereof.
RISK FACTORS
Uncertainties Associated with Clinical Trials
The Company has conducted and plans to continue to undertake extensive and
costly clinical testing to assess the safety, efficacy and applicability of its
potential products. The rate of completion of the Company's clinical trials is
dependent upon, among other factors, the rate of patient enrollment. Patient
enrollment is a function of many factors, including the nature of the Company's
clinical trial protocols, existence of competing protocols, size of the patient
population, proximity of patients to clinical sites and eligibility criteria for
the study. Delays in patient enrollment will result in increased costs and
delays, which could have a material adverse effect on the Company. The Company
cannot assure that patients enrolled in the Company's clinical trials will
respond to the Company's product candidates. Setbacks are to be expected in
conducting human clinical trials. Failure to comply with the United States Food
and Drug Administration ("FDA") regulations applicable to such testing can
result in delay, suspension or cancellation of such testing, and/or refusal by
the FDA to accept the results of such testing. In addition, the FDA may suspend
clinical trials at any time if it concludes that the subjects or patients
participating in such trials are being exposed to unacceptable health risks.
Further, there can be no assurance that human clinical testing will show any
current or future product candidate to be safe and effective or that data
derived therefrom will be suitable for submission to the FDA or will support the
Company's submission of a Biologics License Application ("BLA").
Reliance on Third Party Development and Marketing Efforts
The Company has adopted a research, development and product commercialization
strategy that is dependent upon various arrangements with strategic partners and
others. The success of the Company's products is substantially dependent upon
the success of these outside parties in performing their obligations, which
include, but are not limited to, providing funding, performing research and
development, fulfilling long-term manufacturing demands and marketing,
distribution and sales with respect to the Company's products. The Company's
strategic partners may also develop products that may compete with the Company.
Although the Company believes that its partners have an economic incentive to
succeed in performing their contractual obligations, the amount and timing of
resources that they devote to these activities is not within the control of the
Company. There can be no assurance that these parties will perform their
obligations as expected or that any revenue will be derived from such
arrangements. The Company has entered into collaborative agreements with
Genentech, Zenyaku Kogyo, Ltd. ("Zenyaku"), SmithKline Beecham, Mitsubishi
Chemical Corporation ("Mitsubishi"), Seikagaku Corporation ("Seikagaku") and
Eisai Co., Ltd. ("Eisai"). These agreements generally may be terminated at any
time by the strategic partner, typically on short notice to the Company. If one
or more of these partners elect to terminate their relationship with the
Company, or if the Company or its partners fail to achieve certain milestones,
it could have a material adverse effect on the Company's ability to fund the
related programs and to develop any products that may have resulted from such
collaborations. There can be no assurance that these collaborations will be
successful. In addition, some of the Company's current partners have certain
rights to control the planning and execution of product development and clinical
programs, and there can be no assurance that such partners' rights to control
aspects of such programs will not impede the Company's ability to conduct such
programs in accordance with the schedules currently contemplated by the Company
for such programs and will not otherwise impact the Company's strategy.
Lengthy Regulatory Process; No Assurance of Regulatory Approvals
The testing, manufacturing, labeling, advertising, promotion, export, and
marketing, among other things, of the Company's products are subject to
extensive regulation by governmental authorities in the United States and other
countries. In the United States, pharmaceutical products are regulated by the
FDA under the Federal Food, Drug, and Cosmetic Act and other laws, including, in
the case of biologics, the Public Health Service Act. At the
7
10
present time, the Company believes that its products will be regulated by the
FDA as biologics. Manufacturers of biologics may also be subject to state
regulations.
The steps required before a biologic may be approved for marketing in the United
States generally include (i) preclinical laboratory tests and animal tests, (ii)
the submission to the FDA of an Investigational New Drug application ("IND") for
human clinical testing, which must become effective before human clinical trials
may commence, (iii) adequate and well-controlled human clinical trials to
establish the safety and efficacy of the product, (iv) the submission to the FDA
of a BLA, (v) FDA review of the BLA, and (vi) satisfactory completion of a FDA
inspection of the manufacturing facility or facilities at which the product is
made to assess compliance with Good Manufacturing Practices ("GMP"). The testing
and approval process requires substantial time, effort and financial resources
and there can be no assurance that any approval will be granted on a timely
basis, if at all. There can be no assurance that Phase I, Phase II or Phase III
testing will be completed successfully within any specific time period, if at
all, with respect to any of the Company's potential products. Furthermore, the
FDA may suspend clinical trials at any time on various grounds, including a
finding that the subjects or patients are being exposed to an unacceptable
health risk.
The results of the preclinical studies and clinical studies, together with
detailed information on the manufacture and composition of the product, are
submitted to the FDA in the form of a BLA requesting approval to market the
product. Before approving a BLA, the FDA will inspect the facilities at which
the product is manufactured, and will not approve the product unless GMP
compliance is satisfactory. The FDA may deny a BLA if applicable regulatory
criteria are not satisfied, may require additional testing or information,
and/or may require postmarketing testing and surveillance to monitor the safety
or efficacy of a product. There can be no assurance that FDA approval of any BLA
submitted by the Company will be granted on a timely basis if at all. Also, if
regulatory approval of a product is granted, such approval may entail
limitations on the indicated uses for which it may be marketed.
Both before and after approval is obtained, violations of regulatory
requirements, including the preclinical and clinical testing process, the BLA
review process, or thereafter (including after approval) may result in various
adverse consequences, including the FDA's delay in approving or refusal to
approve a product, withdrawal of an approved product from the market, and/or the
imposition of criminal penalties against the manufacturer and/or license holder.
For example, license holders are required to report certain adverse reactions to
the FDA, and to comply with certain requirements concerning advertising and
promotional labeling for their products. Also, quality control and manufacturing
procedures must continue to conform to GMP regulations after approval, and the
FDA periodically inspects manufacturing facilities to assess compliance with
GMP. Accordingly, manufacturers must continue to expend time, monies and effort
in the area of production and quality control to maintain GMP compliance. In
addition, discovery of problems may result in restrictions on a product,
manufacturer or holder, including withdrawal of the product from the market.
Also, new government requirements may be established that could delay or prevent
regulatory approval of the Company's products under development.
The Company will also be subject to a variety of foreign regulations governing
clinical trials and sales of its products. Whether or not FDA approval has been
obtained, approval of a product by the comparable regulatory authorities of
foreign countries must be obtained prior to the commencement of marketing of the
product in those countries. The approval process varies from country to country
and the time may be longer or shorter than that required for FDA approval. At
least initially, the Company intends, to the extent possible, to rely on foreign
licensees to obtain regulatory approval for marketing its products in foreign
countries.
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs
intended to treat a "rare disease or condition," which generally is a disease or
condition that affects fewer than 200,000 individuals in the United States.
Orphan drug designation must be requested before submitting a BLA. After the FDA
grants orphan drug designation, the generic identity of the therapeutic agent
and its potential orphan use are publicly disclosed by the FDA. Orphan drug
designation does not convey any advantage in, or shorten the duration of, the
regulatory review and approval process. If a product that has an orphan drug
designation subsequently receives FDA approval for the indication for which it
has such designation, the product is entitled to orphan exclusivity, i.e., the
FDA may not approve any other applications to market the same drug for the same
indication, except in certain very limited circumstances, for a period of seven
years.
In 1994, the Company obtained orphan drug designation for IDEC-C2B8, IDEC-Y2B8
and IDEC-In2B8 from the FDA to treat low-grade B-cell lymphoma. There can be no
assurance that any of these compounds will receive orphan exclusivity for the
low-grade B-cell lymphoma indication, and it is possible that competitors of the
Company
8
11
could obtain approval, and attendant orphan drug exclusivity, for these same
compounds for the low-grade B-cell lymphoma indication, thus precluding the
Company from marketing its products for the same indication in the United
States. In addition, even if the Company does obtain orphan exclusivity for any
of its compounds for low-grade B-cell lymphoma, there can be no assurance that
competitors will not receive approval of other, different drugs or biologics for
low-grade B-cell lymphoma. Although obtaining FDA approval to market a product
with orphan drug exclusivity can be advantageous, there can be no assurance that
the scope of protection or the level of marketing exclusivity that is currently
afforded by orphan drug designation will remain in effect in the future.
Additional Financing Requirements and Uncertain Access to Capital Markets
The Company has expended and will continue to expend substantial funds to
complete the research, development, manufacturing and marketing of its products.
The Company may seek additional funding for these purposes through a combination
of new collaborative arrangements, strategic alliances, additional equity or
debt financings or from other sources. There can be no assurance that such
additional funds will be available on acceptable terms, if at all. Even if
available, the cost of funds may result in substantial dilution to current
shareholders. If adequate funds are not available from operations or additional
sources of financing, the Company's business could be materially and adversely
affected.
Limited Manufacturing Experience
The Company has not yet commercialized any therapeutic products. To conduct
clinical trials on a timely basis, to obtain regulatory approval and to be
commercially successful, the Company must manufacture its products either
directly or through third parties in commercial quantities in compliance with
regulatory requirements and at an acceptable cost. Although the Company has
produced its products in the laboratory, scaled its production process to pilot
levels and has the ability to manufacture limited commercial quantities of
certain of its products, the Company has not received regulatory approval for
such production. The Company anticipates that production of its products in
commercial quantities will create technical as well as financial challenges for
the Company. The Company has limited experience in manufacturing, and no
assurance can be given as to the ultimate performance of the Company's
manufacturing facility in San Diego, its suitability for approval for commercial
production or the Company's ability to make a successful transition to
commercial production.
The Company is dependent upon Genentech to fulfill long-term manufacturing
demands for its IDEC-C2B8 product and SmithKline Beecham to fulfill all of the
manufacturing requirements for IDEC-CE9.1. Genentech is currently constructing a
larger manufacturing plant to satisfy such long-term demands. The Company is
considering the addition of another manufacturing facility to meet its long-term
requirements for additional products under development. Failure by the Company
or its strategic partners to establish additional manufacturing capacity on a
timely basis would have a material adverse effect on the Company.
Patents and Proprietary Rights
The Company's success will depend, in large part, on its ability to maintain a
proprietary position in its products through patents, trade secret and orphan
drug designation. The Company holds one issued and one allowed United States
patent, 18 United States patent applications and numerous corresponding foreign
patent applications, and has licenses to patents or patent applications of other
entities. No assurance can be given, however, that the patent applications of
the Company or the Company's licensors will be issued or that any issued patents
will provide competitive advantages for the Company's products or will not be
successfully challenged or circumvented by its competitors. Moreover, there can
be no assurance that any patents issued to the Company or the Company's
licensors will not be infringed by others or will be enforceable against others.
In addition, there can be no assurance that the patents, if issued, would not be
held invalid or unenforceable by a court of competent jurisdiction. Enforcement
of the Company's patents may require substantial financial and human resources.
Moreover, the Company may have to participate in interference proceedings if
declared by the United States Patent and Trademark Office to determine priority
of inventions, which typically take several years to resolve and could result in
substantial cost to the Company.
A substantial number of patents have already been issued to other biotechnology
and biopharmaceutical companies. Particularly in the monoclonal antibody field,
competitors may have filed applications for or have been issued patents and are
likely to obtain additional patents and proprietary rights relating to products
or processes competitive with or similar to those of the Company. To date, no
consistent policy has emerged regarding the breadth of claims allowed in
biopharmaceutical patents, however, patents may issue with claims that conflict
with the Company's
9
12
own patent filings or read on its own products. There can be no assurance that
patents do not already exist in the United States or in foreign countries or
that patents will not be issued that would entail substantial costs to challenge
and that, if unsuccessfully challenged, would have a material adverse effect on
the Company's ability to market its products. Specifically, the Company is aware
of several patents and patent applications which may affect the Company's
ability to make, use and sell its products. Accordingly, the Company expects
that commercializing monoclonal antibody-based products may require licensing
and/or cross-licensing of patents with other companies in this field. There can
be no assurance that the licenses, which might be required for the Company's
processes or products, would be available, if at all, on commercially acceptable
terms. The ability to license any such patents and the likelihood of
successfully contesting infringement or validity of such patents are uncertain
and the costs associated therewith may be significant. If the Company is
required to acquire rights to valid and enforceable patents but cannot do so at
a reasonable cost, the Company's ability to manufacture or market its products
would be materially adversely affected.
The owners, or licensees of the owners, of these patents may assert that one or
more of the Company's products infringe one or more claims of such patents. If
legal action is commenced against the Company to enforce any of these patents
and the plaintiff in such action prevails, the Company could be prevented from
practicing the subject matter claimed in such patents. In such event or under
other appropriate circumstances, the Company may attempt to obtain licenses to
such patents. However, no assurance can be given that any owner would license
the patents to the Company at all or on terms that would permit
commercialization of the Company's products. An inability to commercialize such
products could have a material adverse effect on the Company's operations and
ability to pursue its long-term objectives.
Limited Sales and Marketing Experience
Commercialization of the Company's products is expensive and time-consuming. The
Company has adopted a strategy of pursuing collaborative agreements with
strategic partners that provide for co-promotion of certain of the Company's
products. In the event that the Company elects to participate in co-promotion
efforts in the United States or Canada, and in those instances where the Company
has retained exclusive marketing rights in specified territories, the Company
will need to build a sales and marketing capability in the targeted markets. The
Company currently has a limited marketing staff and no sales personnel. There
can be no assurance that the Company will be able to establish a successful
direct sales and marketing capability in any or all targeted markets or that it
will be successful in gaining market acceptance for its products. To the extent
that the Company enters into co-promotion or other licensing arrangements, any
revenues received by the Company will be dependent on the efforts of third
parties and there can be no assurance that such efforts will be successful.
Outside of the United States and Canada, the Company has adopted a strategy to
pursue collaborative arrangements with established pharmaceutical companies for
marketing, distribution and sale of its products. There can be no assurance that
any of these companies or their sublicensees will successfully market,
distribute or sell the Company's products or that the Company will be able to
establish and maintain successful co-promotion or distribution arrangements.
Failure to establish a sales capability in the United States or outside the
United States may have a material adverse effect on the Company.
History of Operating Losses; Accumulated Deficit
The Company has incurred annual operating losses since its inception in 1985. As
of September 30, 1996, the Company's accumulated deficit was approximately $85.0
million. The Company anticipates that it will continue to incur operating losses
over at least the next one to two years. Such losses have been and will be
principally the result of the various costs associated with the Company's
research and development, clinical and manufacturing activities. The Company has
not generated operating profits from the sale of its products. All revenues to
date have resulted from collaborative research, development and licensing
arrangements, contract manufacturing arrangements, research grants and interest
income. The Company has no products approved by the FDA or any foreign authority
and does not expect to achieve profitable operations on an annual basis unless
product candidates now under development receive FDA or foreign regulatory
approval and are thereafter commercialized successfully.
10
13
Possible Volatility of Stock Price
The stock market has from time to time experienced significant price and volume
fluctuations that may be unrelated to the operating performance of particular
companies. In addition, the market price of the Company's common stock, like the
stock prices of many publicly traded biotechnology companies, has been highly
volatile. Announcements of technological innovations or new commercial products
by the Company or its competitors, developments or disputes concerning patent or
proprietary rights, publicity regarding actual or potential medical results
relating to products under development by the Company or its competitors,
regulatory developments in both the United States and foreign countries, public
concern as to the safety of biotechnology products and economic and other
external factors, as well as period-to-period fluctuations in financial results
may have a significant impact on the market price of the Company's common stock.
It is likely that, in some future quarter, the Company's operating results will
be below the expectations of public market analysts and investors. In such
event, the price of the Company's common stock would likely be materially
adversely affected.
Uncertainties Regarding Health Care Reimbursement and Reform
The future revenues and profitability of biopharmaceutical companies as well as
the availability of capital may be affected by the continuing efforts of
government and third-party payors to contain or reduce costs of health care
through various means. For example, in certain foreign markets pricing or
profitability of prescription pharmaceuticals is subject to government control.
In the United States, there have been, and the Company expects that there will
continue to be, a number of federal and state proposals to implement similar
government controls. While the Company cannot predict whether any such
legislative or regulatory proposals will be adopted, the announcement or
adoption of such proposals could have a material adverse effect on the Company's
business, financial condition or prospects.
The Company's ability to commercialize its products successfully will depend in
part on the extent which appropriate reimbursement levels for the cost of such
products and related treatment are obtained from governmental authorities,
private health insurers and other organizations, such as health maintenance
organizations ("HMOs"). Third-party payors are increasingly challenging the
prices charged for medical products and services. Also, the trend toward managed
health care in the United States and the concurrent growth of organizations such
as HMOs, which could control or significantly influence the purchase of health
care services and products, as well as legislative proposals to reform health
care or reduce government insurance programs may all result in lower prices for
the Company's products. The cost containment measures that health care payors
and providers are instituting and the effect of any health care reform could
materially adversely affect the Company's ability to operate profitably.
Product Liability Exposure
Clinical trials, manufacturing, marketing and sale of any of the Company's or
its strategic partners' pharmaceutical products or processes licensed by the
Company may expose the Company to product liability claims. The Company
currently carries limited product liability insurance. There can be no assurance
that the Company or its strategic partners will be able to continue to maintain
or obtain additional insurance or, if available, that sufficient coverage can be
acquired at a reasonable cost. An inability to obtain sufficient insurance
coverage at an acceptable cost or otherwise protect against potential product
liability claims could prevent or inhibit the commercialization of
pharmaceutical products developed by the Company or its strategic partners. A
product liability claim or recall would have a material adverse effect on the
business and financial condition of the Company.
Environmental Concerns
The Company's research and development involves the controlled use of hazardous
materials, chemicals and radioactive compounds. Although the Company believes
that its safety procedures for handling and disposing of such materials comply
with the standards prescribed by state and federal regulations, the risk of
accidental contamination or injury from these materials cannot be completely
eliminated. In the event of such an accident, the Company could be held liable
for any damages that result and any such liability could exceed the resources of
the Company. In addition, disposal of radioactive materials used by the Company
in its research efforts may only be made at approved facilities. Approval of a
site in California has been delayed indefinitely. The Company currently stores
such radioactive materials on site. The Company may incur substantial cost to
comply with environmental regulations.
11
14
PART II -- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS. None
ITEM 2. CHANGES IN SECURITIES. None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES. None
ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SHAREHOLDERS. None
ITEM 5. OTHER INFORMATION. None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits.
The following exhibits are referenced.
Exhibit
Number Description
------- -----------
10.1 Lease Agreement between the Company and All Spectrum
Services, Inc., dated August 13, 1996.
27.1 Financial Data Schedule
(b) Reports on Form 8-K. None
12
15
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IDEC PHARMACEUTICALS CORPORATION
Date: November 13, 1996 By: /s/ William H. Rastetter
----------------------- ------------------------
William H. Rastetter
Chairman, President and
Chief Executive Officer
(Principal Executive Officer)
Date: November 13, 1996 By: /s/ Phillip M. Schneider
----------------------- ------------------------
Phillip M. Schneider
Vice President and
Chief Financial Officer
(Principal Financial and Accounting Officer)
13
1
EXHIBIT 10.1
LEASE AGREEMENT
THIS LEASE AGREEMENT is made as of the 13th day of August, 1996, by and
between, Professors Fund I, L.P., Managing Agent for All Spectrum Services, Inc.
("Landlord") and IDEC Pharmaceuticals Corporation, a California corporation
("Tenant"), who agree as follows:
ARTICLE 1. DEFINITIONS
As used herein, the following terms shall have the following meanings:
1.1 Premises: Approximately 44,754 square feet, consisting of the entire
Building (which term is defined in Article 2 hereof) located at 3030 Callan
Road, San Diego, California as depicted on Exhibit A attached hereto and
incorporated herein and shall include (1) the exclusive use of the loading dock
shown on Exhibit A and (2) the non-exclusive right to use the Common Areas. The
term "Common Areas" is defined as all areas and facilities outside the Premises
and within the exterior boundary line of the Project that are provided and
designated by Landlord from time to time for the general non-exclusive use of
Landlord, Tenant and other tenants of the Project and their respective
employees, suppliers, shippers, customers and invitees, including parking areas,
trash areas, roadways, sidewalks, walkways, parkways, driveways and landscaped
areas, if any.
1.2 Property and Project: The real property on which the Building is
located as described in Exhibit "A-1" attached hereto and incorporated herein.
The Project shall consist of the Property, the Building and the building located
at 3020 Callan Road containing approximately 46,172 square feet.
1.3 Term: Seven (7) years commencing on the Commencement Date.
1.4 Basic Rent: Shall refer to a monthly amount of $42,516.30 during the
first twelve (12) months of the Lease Term, which is subject to adjustments as
set forth in Article 4 hereof.
1.5 Initial Direct Operating Expenses: Tenant shall pay its Pro-Rata Share
of Direct Operating Expenses pursuant to Section 4.3 below.
1.6 Tenant's Pro-Rata Share: 49.22% which percentage represents the
proportion that the number of approximate square feet of the Premises bears to
the total number of square feet of the Project (44,754 square feet/90,926 square
feet in the Project).
1.7 Commencement Date: November 15, 1996
1.8 Security Deposit: $42,516.30
1.9 Permitted Use: Uses allowed by the City of San Diego Scientific
Research Zoning Ordinance in effect as of the date of this Lease as the same may
be modified from time to time, but excluding any retail or restaurant use, and
for no other use or purpose.
1.10 Tenant's Notice Address: For purposes of Article 19 of this Lease
shall be
11011 Torreyana Road
San Diego, CA 92121
Attn: General Counsel
and V.P. Finance
1
2
With a copy to:
Todd Anson, Esq.
Brobeck, Phleger & Harrison
550 West C Street
Suite 1200
San Diego, CA 92101
1.11 Lease: Shall collectively refer to this Agreement of Lease together
with the following Exhibits and Addenda, attached hereto and incorporated herein
by this reference:
Exhibit A: Project Site Plan
Exhibit A-1: Property Legal Description
Exhibit B: Rules and Regulations
1.12 Broker: Landlord and Tenant recognize that John Burnham & Company
represents Tenant and Colliers International represents the Landlord.
ARTICLE 2. PREMISES
Subject to the terms, provisions and conditions of this Lease, Landlord
hereby leases to Tenant, and Tenant hereby takes and hires from Landlord, the
Premises located in Landlord's building located at 3030 Callan Road, San Diego,
California ("Building"). The location of the Building is more particularly shown
on the attached Exhibit A.
ARTICLE 3. TERM
3.1 Term: The term of this Lease ("Term") shall be for the period
specified in Section 1.3 hereof plus any fraction of a calendar month between
the Commencement Date (hereinafter defined) and the first day of the first full
calendar month of the Term.
3.2 Commencement Date: The Commencement Date shall be November 15, 1996.
Prior to the Commencement Date, Tenant may enter the Premises to construct the
Tenant Improvements in accordance with Article 6 and for related purposes
authorized by this Lease. Such early entry shall be subject to all of the terms
and conditions of this Lease other than the obligation to pay Rent (as defined
below). Without limiting the foregoing, Tenant shall provide to Landlord prior
to such entry evidence of insurance required to be maintained by Tenant pursuant
to this Lease.
ARTICLE 4. RENT
From and after the Commencement Date, Tenant agrees to pay Landlord, in
advance, on the first day of each and every calendar month during the Term, the
Basic Rent, together with rental adjustments as defined below. Such rent for any
fraction of a month at the beginning or end of the Term will be prorated and
paid at the Commencement Date. Payment of all such rent and other charges shall
be without offset, deduction or demand, shall be in lawful money of the United
States of America and shall be made to Landlord at the following address, or at
such place Landlord may direct from time to time by written notice to Tenant:
Professors Fund I, L.P.
as Managing Agent for
All Spectrum Services, Inc.
Attn: Elizabeth J. Clarquist
6170 Cornerstone Court East, Suite 140
San Diego, CA 92121
Such rent and other charges shall include the following:
2
3
4.1 Basic Rent: Subject to annual increases pursuant to Section 4.2 below,
Tenant agrees to pay Landlord on the first day of each month Basic Rent in the
amount specified in Section 1.4 hereof. Tenant shall pay to Landlord,
immediately upon execution of this Lease (in addition to the Security Deposit
required pursuant to Section 4.7 below), the sum of one (1) month's prepaid
Basic Rent which shall be applied to the first full calendar month of the Term
for which payment of Basic Rent is due. Notwithstanding the foregoing, Landlord
will provide Tenant with ten (10) months of conditional rent abatement such that
Basic Rent shall be abated in full during the second through sixth full calendar
months of the Term and during the thirteenth through seventeenth full calendar
months of the Term ("Free Rent Periods"). During the Free Rent Periods, Tenant
shall be responsible for payment of Direct Operating Expenses Rent. If, during
the Free Rent Periods, Tenant defaults under this Lease and fails to cure such
default within any applicable notice and/or cure period set forth herein, the
Free Rent Period shall thereupon terminate, and Tenant shall immediately
commence paying the full amount of Basic Rent under this Lease. In addition, if
at any time during the Term, Tenant defaults under this Lease and fails to cure
such default within any applicable notice and/or cure period set forth herein
and Landlord terminates this Lease as a result of such uncured default, then the
unamortized portion of all Basic Rent conditionally forgiven during the Free
Rent Periods shall become immediately due and payable upon such termination. The
"unamortized portion" of the conditionally forgiven Basic Rent shall be an
amount equal to (a) the amount of conditionally forgiven Basic Rent multiplied
by (b) a fraction, the numerator of which is 74 months minus the number of
months that Tenant has actually paid the full amount of Basic Rent due to
Landlord, and the denominator of which is 74 months. For example, if Tenant
actually pays the full amount of Basic Rent for 20 months, then Tenant shall
repay to Landlord 72.97 percent of the conditionally forgiven Basic Rent (54
months divided by 74 months).
4.2 Annual Increase of Basic Rent: Commencing on the first day of the
thirteenth (13th) calendar month immediately following the Commencement Date,
the remaining Term of the Lease shall be divided into consecutive one year
periods (each of which, including the initial twelve (12) calendar months of the
Term, shall be referred to as "Lease Year"). The Basic Rent provided in Section
4.1 above, shall be increased on the first day of each such Lease Year (i.e., on
the first day of the thirteenth (13th), twenty-fifth (25th), thirty-seventh
(37th), etc., months following the Commencement Date) or, if the Commencement
Date is the first day of a calendar month, on each anniversary of the
Commencement Date ("Adjustment Date"). Each such increase shall be as follows:
---------------------------------------------------------
Months Monthly Basic Rent
---------------------------------------------------------
13 - 24 $44,216.95
---------------------------------------------------------
25 - 36 $45,985.63
---------------------------------------------------------
37 - 48 $47,825.05
---------------------------------------------------------
49 - 60 $49,738.06
---------------------------------------------------------
60 - 72 $51,727.58
---------------------------------------------------------
73 - 84 $53,796.68
---------------------------------------------------------
(i) The increase in Basic Rent provided by this Section 4.2
shall be in addition to Direct Operating Expenses Rent increases provided in
Section 4.3. All references in this Lease to Basic Rent shall include any
increase in Basic Rent.
4.3 Direct Operating Expenses Rent.
(a) From and after the Commencement Date, Tenant agrees to pay to
Landlord, as additional rent, Tenant's Pro-Rata Share of Direct Operating
Expenses (hereinafter defined)
3
4
incurred by Landlord ("Direct Operating Expenses Rent"). Tenant shall pay to
Landlord, Tenant's Direct Operating Expenses Rent pursuant to the following
procedures:
(i) Landlord shall provide to Tenant a good faith estimate of
the annual Direct Operating Expenses and the total amount of annual Direct
Operating Expenses Rent with respect to each calendar year of the Term. Landlord
shall use reasonable efforts to provide each such estimate to Tenant at least
thirty (30) days prior to the end of the calendar year;
(ii) Each estimate of total annual Direct Operating Expenses
Rent determined by Landlord pursuant to this Section , shall be divided into
twelve (12) equal monthly installments. Tenant shall pay to Landlord such
monthly installment of Direct Operating Expenses Rent with each monthly payment
of Basic Rent pursuant to Section 4.1 above. In the event the estimated amount
of Direct Operating Expenses Rent has not yet been determined for any calendar
year, Tenant shall pay the monthly installment in the estimated amount
determined for the preceding calendar year until the estimate for the current
calendar year has been provided to Tenant, at which time Tenant shall, within
thirty (30) days following receipt of the notice pay to Landlord any existing
shortfall and, thereafter, make the monthly installment payment in accordance
with the current estimate;
(iii) As soon as reasonably possible following the end of each
calendar year of the Term, other than the end of any partial calendar year, but
generally no later than sixty (60) days after the end of the calendar year,
Landlord shall determine and provide to Tenant a statement of the amount of
Direct Operating Expenses actually incurred and the amount of Direct Operating
Expenses Rent payable by Tenant with respect to such calendar year, or portion
thereof, for any partial calendar year. In the event the amount of such Direct
Operating Expenses Rent exceeds the sum of the monthly installments actually
paid by Tenant, pursuant to Section 4.3(a)(ii) above, for such calendar year,
Tenant shall pay to Landlord within fifteen (15) days after receipt of
Landlord's written demand accompanied by the final statement, the difference. In
the event the sum of such installments exceeds the amount of Direct Operating
Expenses Rent actually due and owing, the difference shall be applied as a
credit to Direct Operating Expenses Rent payable by Tenant pursuant to Section
4.3(a)(ii). In no event shall the adjustment of Direct Operating Expenses Rent
decrease the amount of Basic Rent due and payable to Landlord under this Lease.
In the case of an overpayment for the final full or partial calendar year of the
Term, Landlord shall refund the overpayment to Tenant within thirty (30) days
after the end of the Term provided that Tenant is not then in default.
(b) For purposes of this Section, the following terms shall have
the following prescribed meanings:
(i) The term "Project" means the Project as defined in Article
1, and the parking areas and other structures and common areas servicing the
Project, and the Property upon which the Project and parking area such other
structures and common areas are located.
(ii) The term "Direct Operating Expenses" as used herein means
all actual operating costs and expenses (without overhead or profit to Landlord
other than the management fee described below) associated with the operation and
maintenance of the Project, exterior landscaping for the Project and such
additional facilities as are now in use or in subsequent years may be determined
by Landlord to be reasonably desirable. All Direct Operating Expenses shall be
determined in accordance with generally accepted accounting principles,
consistently applied. Direct Operating Expenses shall include, by way of
illustration, but not limitation, the following:
(1) Reasonable wages and salaries of all employees in
the proportion that such employees are engaged in operating and maintenance or
security of the Project, including taxes, insurance and benefits relating
thereto, and the reasonable rental value of the Project office.
4
5
(2) All supplies and materials used in operation and
maintenance or security of the Project.
(3) Actual costs of all utilities (other than
electricity not utilized for common areas), including surcharges of the Project
(including the cost of water, sewer, gas, power, heating, lighting, air
conditioning and ventilating for the Project).
(4) Costs of all maintenance and service agreements for
the Project, and equipment therein, including, but not limited to, common area
utility and maintenance charges (including, but not limited to, assessments or
contributions to maintenance associations or special benefit districts);
security and energy management services; window cleaning; road, sidewalk,
driveways and parking facility maintenance or cleaning; and elevator
maintenance.
(5) Cost of all insurance relating to the Project,
including the cost of casualty and liability insurance applicable to the Project
together with Landlord's personal property used in connection therewith, but
excluding the cost of any earthquake insurance coverage during the period that
the Landlord is Professors Fund I, L.P., as Managing Agent for Spectrum
Services, Inc. Any successor Landlord may include the cost of earthquake
insurance as a Direct Operating Expense at any time after the first thirty six
(36) months of the Term if (a) such successor Landlord is required to maintain
earthquake insurance on the Premises by its lender or (b) if it is prudent for
owners of similar buildings in the San Diego area to maintain earthquake
insurance provided that Tenant's Pro-Rata Share of the premiums for such
insurance shall not exceed Twelve Thousand Dollars ($12,000.00) per year during
the initial Term.
(6) Costs of repairs and general maintenance (excluding
repairs and general maintenance paid by proceeds of insurance or by Tenant or
other third parties).
(7) A management fee for the manager of the Project not
to exceed three and one-half percent (3.5%) of Basic Rent. During the initial
seven (7) year Term, the management fee shall not exceed $17,856.85 per year.
(8) The costs of any additional services not provided to
the Project at the Commencement Date but thereafter provided by Landlord in
prudent management of the Project or at the direction of or resulting from
statutes or regulations, or interpretations thereof, promulgated by any
governmental authority in connection with the use or occupancy of the Project
that was not applicable when such improvements were originally constructed.
(9) The costs of any capital improvements or alterations
made to the Project after the Commencement Date that reduce other operating
expenses or are required at the direction of or resulting from, statutes,
ordinances, rules or regulations, or interpretations thereof, promulgated by any
governmental authority in connection with the use or occupancy of the Project
that were not applicable when such improvements were originally constructed,
such cost thereof to be amortized over the useful life of the improvement in
accordance with generally accepted accounting principles, together with interest
on the unamortized balance at the rate of ten percent (10%) per annum or such
higher rate as may be paid by Landlord on funds borrowed for the purpose of
constructing said capital improvements.
(10) All taxes, special taxes, assessments and similar
impositions levied on the Project (including, without limitation, the land upon
which it is located), including, but not limited to, real property taxes and
assessments, and personal property taxes and assessments on all personal
property of Landlord used in connection with the maintenance and operation of
the Project and the reasonable costs incurred by Landlord in contesting, in good
faith and by appropriate proceedings the amount or validity of any such tax or
assessment.
Direct Operating Expenses shall exclude the following:
5
6
(1) Real estate taxes levied on or with respect to any
parking garage or facility included in the Project, or any personal property
taxes payable by Tenant or by other tenants of the Project;
(2) Repairs or other work occasioned by fire, windstorm
or other casualty (except for the cost of such repairs or other work that
relates to the deductible portion of the insurance policy covering such
casualty) or by the exercise of the right of eminent domain;
(3) The cost of repairing any defects in the design,
materials or workmanship of the Premises, Building or the Project to include
foundation and structural components of the walls and roof, unless caused by
Tenant in which case Tenant shall be responsible for such cost;
(4) Leasing commissions, accountants' or attorneys'
fees, costs and disbursement and other expenses incurred in connection with
proposals, negotiations, or disputes with tenants or other occupants or
prospective tenants or other occupants, or associated with the enforcement of
any leases, disputes with contractors, or the defense of Landlord's title to or
interest in the Premises or the Project or any part thereof;
(5) Costs (including permit, license and inspection
fees) incur-red in constructing tenant improvements or decorating, painting or
redecorating space for other tenants or other occupants or vacant rentable
space;
(6) Depreciation and amortization of the Building;
(7) Interest on debt or amortization payments on any
mortgages or deeds of trust or any other borrowings;
(8) Advertising and promotional expenditures;
(9) Damage and repairs necessitated by the negligence or
willful misconduct of Landlord or Landlord's, employees, contractors or agents;
(10) Executive salaries or salaries of service personnel
to the extent that such service personnel perform services other than in
connection with the management, operation, repair or maintenance of the
Premises, the Project or the Common Areas;
(11) Costs or fines arising from Landlord's violation of
any governmental rule or authority;
(12) Costs exceeding those reasonably obtainable by a
reasonably prudent owner;
(13) Costs arising from Landlord's charitable or
political contributions;
(14) Costs incurred to test, survey, cleanup, contain,
abate, remove or otherwise remedy Hazardous Substances(as defined in Article 37)
from the Premises; and
(15) Costs to replace the existing coolant in the
Building's air conditioning system for the first time during the Term, provided
that subsequent replacements shall be included in Direct Operating Expenses.
(c) Tenant shall have the right to audit Landlord's books and
records relating to Direct Operating Expenses, provided that any audit of Direct
Operating Expenses for any calendar year must be commenced within three (3)
years after the end of such calendar year and that Tenant may not audit the
books and records relating to any calendar year more than once. Tenant shall be
solely responsible for all costs and expenses of any audit unless the audit
shows that
6
7
Tenant was overcharged for Direct Operating Expenses by more than five percent
(5%), in which event Landlord shall pay Tenant's reasonable out of pocket costs
and expenses of the audit; provided, however, that Landlord shall have the right
to contest the results of the audit in good faith.
4.4 Additional Rent. Tenant shall pay to Landlord as additional rent
("Additional Rent") and without notice, abatement, deduction or set off, all
sums, costs and expenses which Tenant, in any of the provisions of this Lease,
assumes or agrees to pay, including, but not limited to, tenant improvement
work, whether or not any of such sums, costs and expenses are specifically
described in this Lease as Additional Rent. In the event of any non-payment of
Additional Rent when required under this Lease, the Landlord shall have (in
addition to all other rights and remedies) all the rights and remedies provided
herein or by law in the case of non-payment of Basic Rent and Direct Operating
Expenses Rent. All references in this Lease to Rent shall mean and collectively
refer to Basic Rent, Direct Operating Expenses Rent and Additional Rent.
4.5 Late Charges. Tenant's failure to pay Basic Rent and Tenant's Pro-Rata
Share of Direct Operating Expenses promptly on the first day of each month may
cause Landlord to incur unanticipated costs, the exact amount of which are
impractical or extremely difficult to ascertain. Such costs may include, but are
not limited to, processing and accounting charges and late charges which may be
imposed on Landlord by any ground lease, mortgage or trust deed encumbering the
Building. Therefore, if Landlord does not receive any Rent payment within five
(5) days after it becomes due, and if such failure continues for three (3) days
after notice (which may be given by telephone or facsimile) thereof to Tenant,
Tenant shall pay Landlord a late charge equal to five percent (5%) of the
overdue amount, provided that if Tenant is more than five (5) days late in the
payment of any Rent more than a total of five (5) times during the Term, then
such late charge shall apply to any payment of Rent not made within five (5)
days after the due date without the requirement of any notice. Notwithstanding
the foregoing, only late payments of Basic Rent and Tenant's Pro-Rata Share of
Direct Operating Expenses shall be subject to a late charge. The parties agree
that such late charge represents a fair and reasonable estimate of the costs
Landlord will incur by reason of such late payment.
4.6 Interest. Any amount owed by Tenant to Landlord which is not paid when
due shall bear interest at the rate of twelve percent (12%) per annum from the
due date of such amount; provided, however, if Tenant pays any Basic Rent or
Tenant's Pro-Rata Share of Direct Operating Expenses prior to the date that a
late charge becomes due under Section 4.5, then no interest shall be due on such
payment. However, interest shall not be payable on late charges to be paid by
Tenant under this Lease. The payment of interest on such amounts shall not
excuse or cure any default by Tenant under this Lease. If the interest rate
specified in this Lease is higher than the rate permitted by law, the interest
rate is hereby decreased to the maximum legal interest rate permitted by law.
4.7 Security Deposit. Tenant shall pay to Landlord, immediately upon
execution of this Lease, the Security Deposit, which shall be held by Landlord
as security for the faithful performance by Tenant of all of the terms,
covenants and conditions of this Lease to be kept and performed by Tenant during
the Term hereof. If Tenant defaults with respect to any provision of the Lease,
including but not limited to, the provisions relating to the payment of Rent,
Landlord may (but shall not be required to) use, apply or retain all or any part
of the Security Deposit for the payment of any Rent or any other sum in default,
or for the payment of any other amount which Landlord may spend or become
obligated to spend by reason of Tenant's default or to compensate Landlord for
any other loss or damage which landlord may suffer by reason of Tenant's
default. If any portion of the Security Deposit is so used or applied, Tenant
shall, upon demand therefor, deposit with Landlord cash, in an amount sufficient
to restore the Security Deposit to its original amount and Tenant's failure to
do so shall be a material breach of this Lease. Landlord shall not be required
to keep the Security Deposit separate from its general funds, and Tenant shall
not be entitled to interest on the Security Deposit. If Tenant shall fully and
faithfully perform every provision of this Lease to be performed by it, the
Security Deposit or any balance thereof shall be returned to Tenant at the
expiration of the Term, provided that Landlord may retain the Security
7
8
Deposit until such time as any amount due from Tenant in accordance hereof has
been determined paid in full.
ARTICLE 5. USE
5.1 Permitted Use. Tenant may use the Premises solely for the Permitted
Use and for no other use without the written consent of Landlord, which shall
not be unreasonably withheld or delayed.
5.2 Compliance with Laws. Tenant shall comply with all laws, ordinances,
rules and regulations pertaining to the use of the Premises and/or Building or
the Tenant Improvements constructed by Tenant, including all requirements of the
Americans With Disabilities Act ("ADA") triggered by construction of the Tenant
Improvements and affecting the interior portions of the Premises, except that
Landlord agrees to pay fifty percent (50%) of the cost to bring the stairwell
within the building located at 3020 Callan Road into compliance with the ADA and
Landlord shall comply with the requirements of the ADA affecting the exterior of
the Premises up to and including the front door and door threshold as provided
in Section 6.1 below. Landlord shall comply with all laws, ordinances, rules and
regulations pertaining to the roof, exterior walls or foundation of the
Building. Tenant shall not do or permit anything to be done in or about the
Premises which will, in any way, obstruct or interfere with the rights of other
tenants or occupants of the Building, or injure them, or allow the Premises to
be used for any immoral or unlawful purpose, nor shall Tenant cause, maintain or
permit any nuisance in, on or about the Premises. Tenant agrees to abide by all
reasonable rules and regulations established by Landlord from time to time with
respect to the Building provided they do not conflict with this Lease. A copy of
the rules and regulations in existence on the date of this Lease is attached
hereto as Exhibit "B", but Landlord reserves the right to reasonably and in a
non-discriminatory manner amend the rules and regulations at any time by giving
notice of amendment to Tenant, if Landlord determines such amendments to be in
the best interest of the Building and its tenants. Landlord shall enforce the
rules and regulations in a non-discriminatory manner.
5.3 Insurance Use Requirements. Tenant shall neither use nor occupy the
Premises in any manner, nor commit or omit any act, which would result in a
cancellation or reduction of any insurance or increase in premiums on any
insurance policy covering the Premises, or the property or Building. Landlord
shall provide notice to Tenant of any changes in insurance as a result of
Tenant's act or omission promptly after Landlord learns of such changes, at
which time Tenant shall pay any increased insurance costs incurred by Landlord
as of such date and shall either modify such use or occupancy to the extent
necessary to avoid any increase in premiums or pay any increase in premiums as a
result of its use or occupancy. Tenant shall, at its expense, comply with all
requirements of any insurer pertaining to use of the Premises and any other
requirement which are reasonably necessary for the maintenance of economic and
proper fire, liability and other insurance desired to be carried by Landlord.
ARTICLE 6. IMPROVEMENTS TO THE PREMISES
6.1 As-Is Condition. Landlord will lease the Premises to Tenant in its
"As-Is" condition without any improvements, representations or warranties,
except that Landlord shall, at its expense, ensure that all plumbing, electrical
and mechanical and other building systems serving the Premises will be in good
working order on the Commencement Date and that the Premises will comply with
all governmental codes and regulations, including requirements of the ADA, but
only to the extent applicable to general use of the Premises and not to any
specific use of Tenant, and, except as provided in Section 5.2 above, excluding
any requirements affecting the interior of the Premises triggered by
construction of the Tenant Improvements (as defined below) by Tenant. Landlord
warrants that the HVAC system shall be in good working order for two months
after the Commencement Date.
6.2 Tenant Improvements. Except as specifically provided in Section 6.1,
any improvements to the Premises required or desired by Tenant ("Tenant
Improvements") shall be constructed at Tenant's sole cost and expense, including
the cost of space planning, construction
8
9
documents, permits and fees. All plans and specifications for the Tenant
Improvements shall be subject to the prior written approval of Landlord, which
approval shall not be unreasonably withheld or delayed. Tenant acknowledges and
agrees that Landlord agreed to lease the Premises to Tenant at the Basic Rent
stated herein and to provide Tenant with the Free Rent Periods based on Tenant's
agreement to expend at least a minimum amount of funds on Tenant Improvements.
Accordingly, Landlord shall have the right to review and approve a description
of the Tenant Improvements to be constructed by Tenant, which approval shall not
be unreasonably withheld or delayed. Unless Landlord and Tenant otherwise agree
in writing, all Tenant Improvements shall be the property of Landlord. All
Tenant Improvements shall be performed in accordance with Sections 7.3 and 7.4
below. Landlord shall receive copies of all building permits relating to the
Tenant Improvements.
ARTICLE 7. MAINTENANCE, REPAIR AND ALTERATION OF PREMISES
7.1 Maintenance. By taking possession of the Premises, Tenant shall be
deemed to have accepted the Premises as being in good, sanitary order,
condition, and repair. Tenant shall, at Tenant's sole cost and expense, keep and
maintain the interior, non-structural portions of the Premises and every part
thereof in good condition and repair, ordinary wear and tear excepted,
including, without limitation, maintenance and repair of the heating,
ventilation and air conditioning system but excluding any capital improvements
that are Landlord's responsibility. Except as specifically provided in Section
6.1 of this Lease, Landlord shall have no obligation whatsoever to alter,
remodel, improve, repair, decorate or paint the interior of the Premises or any
part thereof, and the parties hereto affirm that Landlord has made no
representations to Tenant respecting the condition of the Premises or the
Building.
7.2 Repairs. Notwithstanding the provisions of Section 7.1 above,
Landlord, as a Direct Operating Expense (subject to the exclusions set forth in
Section 4.3 above), shall repair and maintain the water cooling tower serving
the Project, fire and life safety systems for the Building, the elevators in the
Building, and the exterior and structural portions of the Building (which shall
only consist of the roof, the foundation and the exterior walls) in good
condition unless such maintenance and repairs are caused in part or in whole by
the act, neglect, fault, or omission of any duty by the Tenant, its agents,
servants, employees, contractors, licensees or invites, in which case Tenant
shall pay Landlord the reasonable cost of such maintenance and repairs. Landlord
shall not be liable for any such repairs or to perform any maintenance unless
such failure shall persist for an unreasonable time after written notice of the
need of such repairs or maintenance is given to Landlord by Tenant. In making
such repairs, Landlord shall use reasonable efforts to minimize interference
with Tenant's business and the interruption or reduction in services to Tenant.
Except as provided in Article 13 hereof, there shall be no abatement of any item
of Rent and no liability of Landlord by reason of any injury to or interference
with Tenant's business arising from the making of any repairs, alterations, or
improvements in or to any portion of the Building or the Premises or in or to
fixtures, appurtenances, and equipment therein. Tenant waives the right to make
repairs at Landlord's expense under any law, statute, or ordinance now or
hereafter in effect. However, if Landlord fails to perform any repairs or
maintenance required of Landlord under this Section 7.2, and such failure
substantially interferes with Tenant's use and enjoyment of the Premises, then
Tenant may provide written notice of such failure and of Tenant's intention to
perform such repairs or maintenance. If Landlord does not commence such repairs
and maintenance within thirty (30) days after delivery of Tenant's notice, and
thereafter use reasonable due diligence to complete such repairs and
maintenance, Tenant may complete such repairs and maintenance and may offset the
reasonable costs and expenses incurred by Tenant to do so against Tenant's
Pro-Rata Share of Direct Operating Expenses to the extent that such costs and
expenses exceed the amount that would have been payable by Tenant as its
Pro-Rata Share of Direct Operating Expenses had such repairs and maintenance
been performed by Landlord.
7.3 Alterations. Tenant shall not make any alteration, addition, or
improvement to the Premises (whether structural or non-structure) other than
non-structural alterations with a cost of less than $20,000 without the prior
written consent of Landlord, which consent will not be unreasonably withheld or
delayed. In the event Landlord gives its consent, such consent may be
conditioned upon the requirement that Tenant (i) supply to Landlord, plans and
specifications which must be
9
10
approved by Landlord in writing prior to commencement of any work; and (ii)
provide, prior to the commencement of any work, a lien free completion bond and
insurance policies relating to such work in the forms and amounts reasonably
satisfactory to Landlord. Any alteration, addition, or improvement for which
Landlord gives its written consent shall be accomplished by Tenant in a good and
workmanlike manner, in conformity with all applicable laws and regulations and
by a contractor reasonably approved by Landlord. Upon completion of any such
work, Tenant shall provide to Landlord "as-built" plans, copies, and proof of
payment of all labor and materials. Tenant shall pay, when due, all claims for
such labor and materials and shall give Landlord at least ten (10) days prior
written notice of the commencement of any such work, whether or not Landlord's
consent is required. Landlord may enter upon the Premises, in such case, for the
purpose of posting appropriate notices, including, but not limited to, notices
of non-responsibility.
7.4 Liens. Tenant shall keep the Premises free from any liens arising out
of any work performed, materials furnished, or obligations incurred by or for
Tenant. In the event that Tenant shall not, within ten (10) days following the
imposition of any such lien, cause the same to be released of record by payment
or posting of a proper bond, Landlord shall have, in addition to all other
remedies provided herein and by law, the right, but not the obligation, to cause
the same to be released by such means as it shall deem proper, including payment
of or defense against the claim giving rise to such lien. All sums paid by
Landlord and all expenses incurred by it in connection therewith shall create
automatically an obligation of Tenant to pay an equivalent amount as additional
rent, which additional rent shall be payable by Tenant on Landlord's demand with
interest at the maximum rate per annum permitted by law until paid.
7.5 Condition on Termination. Upon the expiration, or sooner termination,
of the Lease, Tenant shall surrender the Premises to Landlord, broom clean, and
in the same condition as received, except for ordinary wear and tear which
Tenant was not otherwise obligated to remedy, under any provision of this Lease.
Except for Tenant Improvements approved by Landlord and installed in connection
with the commencement of this Lease, Landlord may require Tenant to remove any
alterations, additions or improvements made by Tenant prior to the termination
of the Lease and to restore the Premises to its prior condition (i.e., the
condition as of the Commencement Date), all at Tenant's expense; provided,
however, that Tenant shall not be required to remove any alterations, additions
or improvements consented to by Landlord unless Landlord informs Tenant when it
gives consent that Tenant will be required to remove such items. All
alterations, additions, and improvements which Landlord does not require Tenant
to remove, including all of the Tenant Improvements, shall become Landlord's
property and shall be surrendered to Landlord upon termination of the Lease.
Except for the Tenant Improvements which shall remain the property of Landlord,
Tenant may remove its alterations, additions and improvements to the Premises
upon the expiration or earlier termination of the Term provided that Tenant
promptly repairs any damage to the Premises caused by such removal.
ARTICLE 8. UTILITIES AND SERVICES
8.1 Utilities and Services Furnished by Landlord. Provided Tenant is not
in default hereunder, Landlord shall furnish air conditioning and heating
services to the Premises. Such services shall be furnished between the hours of
7:00 a.m. and 7:00 p.m., Monday through Friday, and 7:00 a.m. to 1:00 p.m. on
Saturday (legal holidays excluded) excepting electricity to the Premises which
shall be furnished by Tenant. All of the foregoing utilities and services
provided by Landlord shall be included in the Direct Operating Expenses. The
common area electrical, air conditioning and heating services furnished by
Landlord are not represented by Landlord to be adequate for any purpose other
than the Permitted Use. It is acknowledged that the Landlord does not provide an
uninterrupted source of electrical power and other services. Under no
circumstance shall Landlord be liable to Tenant if any utility service to the
Premises and/or Building is interrupted or terminated because of repairs,
installations, improvements or causes beyond Landlord's reasonable control, nor
shall any such interruption or termination be construed as an eviction (actual
or constructive) of Tenant, nor entitle Tenant to an abatement of any item of
Rent, nor relieve Tenant from fulfillment of any covenant or condition of this
Lease. If any such interruption of utility service is caused by the negligence
or willful misconduct of Landlord or its agents, contractors or employees, and
if Tenant is not reasonably able to conduct its business from
10
11
the Premises as a result of such interruption for more than three (3) business
days, then Tenant shall have the right to full abatement of Rent for so long as
such interruption continues after the end of such three (3) business day period
and, if Tenant is so prevented from reasonably operating its business for more
than one hundred eighty (180) days, Tenant shall have the right to terminate
this Lease by delivering written notice of termination to Landlord at any time
prior to the date that such utility service is restored. If Tenant so elects to
terminate this Lease, such termination shall become effective thirty (30) days
after delivery of Tenant's notice to Landlord unless the utility service is
restored to the Premises within such thirty (30) day period. Services and
utilities (including, but not limited to air conditioning) shall also be
provided by Landlord, at an hourly rate established by Landlord from time to
time, during additional hours on reasonable notice to Landlord, at Tenant's sole
cost and expense, and payable by Tenant, as billed, as Additional Rent.
8.2 Other Utilities and Services. Except as set forth in Sections 8.1 and
8.3, Tenant shall furnish and pay, at Tenant's sole expense, all electrical
service inside the Premises, all special electrical and HVAC requirements,
telephone, cable and other services which Tenant requires with respect to the
Premises.
8.3 Janitorial Services Provided by Tenant. Tenant shall be responsible
for janitorial services for the Premises consistent with practices found in
similar buildings.
ARTICLE 9. TAXES
Tenant shall pay, prior to delinquency, all personal property taxes and
license fees levied, assessed or imposed by reason of Tenant's use of the
Premises, and all taxes on Tenant's personal property located on the Premises.
Landlord shall pay all property taxes or assessment with respect to the
Building, which shall be included in Direct Operating Expenses.
ARTICLE 10. LANDLORD'S RIGHT TO ALTER BUILDING
10.1 Landlord's Right to Alter Building. Landlord reserves and shall, at
any and all times, have the right to alter the Building (including, but not
limited to, the parking areas and adjoining common areas) or add thereto, and
may for the purpose erect scaffolding and all other necessary structures,
provided that such actions do not unreasonably interfere with Tenant's use and
enjoyment of the Premises. Landlord also reserves the right to install, use,
maintain, repair and replace pipes, ducts, conduits, wires and appurtenant
meters and equipment for service to other parts of the Building above the
ceiling surfaces, below the floor surfaces, within the walls and in the central
core areas, and to relocate any pipes, ducts, conduits, wires and appurtenant
meters and equipment which are located within the Premises or outside the
Premises, provided that such actions do not unreasonably interfere with Tenant's
use and enjoyment of the Premises.
ARTICLE 11. SIGNS
11.1 Landlord shall maintain, as a Direct Operating Expense, the monument
sign for the Project. Landlord, at its sole cost and expense, shall remove the
signage of American Residential Mortgage on the Building prior to the
Commencement Date.
11.2 Tenant shall not place or permit to be placed, any sign,
advertisement, notice or other similar matter on the doors, windows, exterior
walls, roof or other areas of the Premises and/or Building which are open to the
view of persons in the common area of the Building or grounds, except in
compliance with all applicable legal requirements and with the advance written
consent of Landlord, which consent shall not be unreasonably withheld or
delayed. If any sign, advertisement, notice or similar matter is improperly
placed by Tenant, Landlord shall have the right to remove the same, and Tenant
shall be liable for any and all expenses incurred by Landlord by the removal.
Any signs, advertisement, notice or similar matter (including, but not limited
to, directories and nameplates) approved by Landlord shall be at the sole cost
and expense of Tenant, except as otherwise provided.
11
12
ARTICLE 12. LIABILITY INSURANCE AND INDEMNITY
12.1 Tenant Insurance. Tenant, at its own expense, shall provide and keep
in force with insurance companies authorized to do business in California having
a Best's rating of at least "B+:VII" the following insurance policies:
(a) Broad form commercial general liability insurance, or
equivalent, written on an occurrence form against liability for bodily injury
and property damage arising out of or in connection with the use, occupancy or
maintenance by Tenant of the Premises (including, without limitation, personal
injury coverage and contractual liability insurance specifically covering
liability with respect to the indemnity described in section 12.4 below) in the
amount of not less than Three Million Dollars ($3,000,000.00) in respect to
injuries or death, and in the amount of not less than Three Hundred Thousand
Dollars ($300,000.00) per occurrence in respect to damage to property;
(b) Fire insurance with standard form extended coverage endorsement
to the extent of at least one hundred percent (100%) of the full insurable value
of the Tenant Improvements, other additions, alterations and improvements to the
Premises installed at Tenant's expense, and all trade fixtures, fixtures,
equipment and other personal property which may, from time to time, be located
upon the Premises; and
(c) Such other insurance as Tenant or Landlord or any beneficiary of
any deed of trust encumbering the Building or the Property of which the Premises
are a part, may from time to time, reasonably require, in form, amount and
protecting against such risks as would be obtained by a prudent person.
Each of the foregoing policies of insurance shall name the Landlord and
any mortgagee as an additional insured. Tenant may maintain such insurance as
part of blanket policies containing a "per project, per location" endorsement.
Landlord makes no representation that the minimum insurance amounts specified
above are adequate to protect Tenant, and the amount of insurance obtained by
Tenant shall not limit Tenant's liability under this Lease. Tenant shall furnish
Landlord with a certificate of such policy and certified copies of all required
endorsements prior to taking possession of the Premises or occupying any part
thereof and whenever requested shall satisfy Landlord that such policy is in
full force and effect. Each policy shall be primary and non-contributing with
any insurance carried by Landlord. Each policy shall further provide that it
shall not be canceled or altered without thirty (30) days prior written notice
to Landlord.
12.2 Landlord Insurance. Landlord shall carry (i) "all risk" property
damage insurance with respect to the Building on a full replacement cost basis,
(ii) commercial general liability insurance (or equivalent) on an occurrence
basis and of the type and in the amounts as Landlord shall deem reasonably
appropriate and (iii) such other reasonable and customary insurance with respect
to the Building, that Landlord shall deem reasonably appropriate or that is
required by Landlord's lender for the Project, including rental loss insurance
covering rental losses that would occur if Tenant is entitled to abatement of
Rent due to casualty, interruption of utility services and similar events. The
cost of any such insurance shall be included in the Direct Operating Expenses.
In addition, in the event Tenant fails to provide or keep in force any of the
insurance as required pursuant to Section 12.1 above, Landlord, in its
discretion, may provide such insurance, in which event, the cost thereof shall
be payable by Tenant to Landlord, as Additional Rent on the first day of the
calendar month immediately following demand therefor from Landlord. All
insurance policies required to be maintained by Landlord shall be issued by
insurance companies authorized to do business in California having a Best's
rating of at least "B+:VII."
12.3 Waiver of Liability of Landlord. Landlord shall not be liable to
Tenant for any injury or damage that may result to any person or property by or
from any cause whatsoever (including, without limiting the generality of the
foregoing, injury or damage due to water leakage of any character from the
walls, basement or other portion of the Premises or Building or caused by gas,
fire, oil, electricity or any use whatsoever, in, on or about the Premises or
Building or any part
12
13
thereof, or theft), other than injury or damage resulting from the negligence or
willful misconduct of Landlord or its agents, employees or contractors or
Landlord's breach of this Lease.
12.4 Indemnity by Tenant of Landlord. Tenant agrees to indemnify, hold
Landlord and its agents, employees, affiliates, officers, directors and
shareholders (collectively, the "Indemnitees") harmless from and defend Landlord
and the Indemnitees against any and all claims, damages, costs, expenses
(including attorneys' fees and costs incurred in connection therewith or to
enforce this indemnity obligation) and liabilities for any injury or damage to
any person or property whatsoever (i) occurring in, on or about the Premises or
any part thereof, or (ii) occurring in, on or about any the Property (including,
without prejudice to the generality of the term "Property", passageways or
hallways) the use of which Tenant may have in conjunction with other tenants of
the Building, when such injury or damage shall be caused in part or in whole, by
the act, negligence or fault of, or omission of any duty with respect to the
same by Tenant, its agents, servants or employees, except to the extent caused
by the negligence or willful misconduct of Landlord or its agents, employees or
contractors or by Landlord's breach of this Lease. In case any action, suit or
proceeding is brought against Landlord and/or the Indemnitees for which Tenant
is required to provide indemnity pursuant to this Section , Tenant, upon
Landlord's request and at Tenant's sole cost and expense, will resist and defend
such action, suit or proceeding or cause the same to be resisted and defended by
counsel designated by Tenant and approved by Landlord, or counsel designated by
the insurer whose policy covers the cost, claim, damage or liability. At
Landlord's election, Landlord may select and employ counsel to resist and defend
the action, suit or proceeding and Tenant will reimburse Landlord for any legal
fees or costs incurred by Landlord in connection therewith. The obligations of
Tenant under this section will survive the expiration or any termination of this
Lease.
12.5 Waiver of Subrogation. Landlord and Tenant agree to cause the
insurance companies issuing their respective property insurance to waive any
subrogation rights that those companies may have against Tenant or Landlord,
respectively, as long as the insurance is not invalidated by the waiver. If the
waivers of subrogation are contained in their respective insurance policies,
Landlord and Tenant waive any right that either may have against the other on
account of any loss or damage to their respective property to the extent that
the loss or damage is insured under their respective insurance policies.
ARTICLE 13. DAMAGE OR DESTRUCTION AND CONDEMNATION
13.1 Duty to Restore. In the event the Premises or the Building of which
the Premises are a part are destroyed or damaged as a result of any cause, then
Landlord shall forthwith repair the same, provided the extent of the destruction
or damage can be repaired within one (1) year after the date of damage or
destruction and the insurance proceeds available to Landlord are adequate to
complete such repairs. In the event the destruction of the Premises or the
Building is to an extent that the estimated repair period exceeds one (1) year
from the date of damage or destruction or such available insurance proceeds are
not adequate, then Landlord shall have the option (i) to repair or restore such
damage and this Lease will continue in full force and effect, except that Tenant
shall be entitled to a proportionate reduction of Basic Rent while such repairs
are being made, such proportionate reduction to be based upon the extent to
which the making of such repairs shall materially interfere with the business
carried on by Tenant in the Premises (provided, however, that if the damage is
due to the fault or neglect of Tenant or its employees, there shall be no
abatement of Basic Rent); or (ii) give notice to Tenant at any time within sixty
(60) days after such damage terminating this Lease as of the date of the damage
or destruction. In the event of giving such notice, this Lease shall expire and
all interest of the Tenant in the Premises shall terminate as of the date of the
damage or destruction. Tenant shall have the right to terminate this Lease upon
written notice delivered to Landlord no later than sixty (60) days after the
date of such damage if (i) the estimated repair period exceeds one (1) year from
the date of the damage or (ii) during the last twelve (12) months of the Term of
this Lease, such estimated repair period exceeds ninety (90) days. In addition,
Tenant may terminate this Lease if any such repairs are not completed within one
(1) year after the date of the damage by delivering written notice of
termination to Landlord at any time prior to completion of the repairs, in which
event this Lease
13
14
shall terminate unless Landlord completes the repairs within thirty (30) days
after the date Tenant's termination notice is delivered to Landlord.
13.2 Exclusions from Duty to Restore. Notwithstanding anything to the
contrary contained in this Article:
(a) Landlord shall not have any obligation whatsoever to repair,
reconstruct or restore the Premises when the damage resulting from any casualty
covered under this article occurs during the last twelve (12) months of the term
of this Lease or any extension thereof.
(b) Landlord shall not be required to repair any damage by fire or
other cause, or to make any repairs or replacements of any panels, decoration,
office fixtures, railings, floor covering, partitions, or any other property
installed in the Premises by Tenant.
(c) Tenant shall not be entitled to any compensation or damages from
Landlord for loss of the use of the whole or any part of the Premises. Tenant's
personal property or any inconvenience or annoyance occasioned by such damage,
repair, reconstruction or restoration.
13.3 Total Taking. If the whole of the Premises or so much thereof as to
prevent Tenant from reasonably operating its business within the balance of the
Premises shall be taken under power of eminent domain, this Lease shall
automatically terminate as of the date of such condemnation, or as of the date
possession is taken by the condemning authority, whichever is earlier. If a
partial taking prevents Tenant from reasonably operating its business within the
balance of the Premises, Tenant shall give written notice thereof to Landlord
within thirty (30) days of the taking. No award of any partial or entire taking
shall be apportioned and Tenant hereby assigns to Landlord any award which may
be made in such taking or condemnation, together with any and all rights of
Tenant now or hereafter arising in or to the same or any part thereof; provided,
however, Tenant shall be entitled to any award made to Tenant for the taking of
personal property and fixtures belonging to Tenant or for Tenant's relocation
costs or business interruption compensation.
13.4 Partial Taking. In the event of a partial taking of the Premises
which does not result in a termination of this Lease pursuant to Section 13.3,
rent shall be abated, effective as of the date possession of the Premises is
required to be surrendered, in proportion to the part of the Premises that
Tenant cannot reasonably use to operate its business within the Premises.
Landlord shall restore the portion of the Premises remaining usable to as near
its former condition as reasonably possible using that portion of the
condemnation award attributable to such restoration costs.
13.5 Temporary Taking. No temporary taking of the Premises and/or of
Tenant's rights therein or under this Lease shall terminate this Lease or give
Tenant any right to any abatement of rent hereunder. Any award made to Tenant by
reason of any such temporary taking shall belong entirely to Tenant and Landlord
shall not be entitled to share therein.
13.6 Sale. A sale by Landlord to any authority having the power of eminent
domain, either under threat of condemnation or while condemnation proceedings
are pending, shall be deemed a taking under the power of eminent domain for all
purposes under this Article 13.
13.7 Waiver. Tenant hereby waives any right under any statutes,
ordinances, court decisions or other application law, whether existing now or in
the future, to terminate this Lease following any taking, condemnation, damage
or destruction of the Premises and/or the Building.
ARTICLE 14. DEFAULT BY TENANT
14.1 Remedies Upon default. Tenant agrees that (i) if Tenant fails to make
a payment of any item of Rent and such failure continues for a period of five
(5) days after written notice thereof; or (ii) if Tenant fails to faithfully
perform or observe any other agreement and such failure continues for a period
of thirty (30) days after written notice thereof; unless Tenant commences to
cure the
14
15
failure within thirty (30) days and diligently and continuously proceeds to
complete the cure as soon as reasonably possible, but in no event later than
ninety (90) days, or (iii) if the Premises be vacated or abandoned; or (iv) if
Tenant makes a general assignment for the benefit of its creditors and becomes
unable to pay its debts as they become due in the normal course, or shall file a
petition for bankruptcy or other reorganization, liquidation, dissolution or
similar relief; or (v) a proceeding is filed against Tenant seeking any relief
mentioned in (iv) above unless the same is dismissed within sixty (60) days; or
(vi) a trustee, receiver or liquidator shall be appointed for Tenant or a
substantial part of its property where possession is not restored to Tenant
within sixty (60) days; or (vii) if Tenant's lease interest is sold under
execution, then any such events shall constitute a breach of this Lease and
Landlord may, at Landlord's option, exercise any or all rights available to a
Landlord under the laws of the State of California, including, without
limitation, the right to do any of the following:
(a) Terminate the Lease and recover:
(i) The worth at the time of award of unpaid rent and other
charges which had been earned at the time of such termination; plus
(ii) The worth at the time of the award of the amount by which
the unpaid rent and other charges which would have been earned after termination
until the time of award exceeds the amount of such rental loss which Tenant
proves could have been reasonably avoided; plus
(iii) The worth at the time of award of the amount by which
the unpaid rent and other charges for the balance of the Term of this Lease
after the time of award exceeds the amount of such rental loss which Tenant
proves reasonably could be avoided; plus
(iv) Any other amount necessary to compensate Landlord for all
the detriment proximately caused by Tenant's failure to perform its obligation
under this Lease or which in the ordinary course of things would be likely to
result therefrom, including but not limited to the cost of restoring the
Premises to the condition required in Article 7.5 of this Lease; plus
(v) At Landlord's election, such other amounts in addition to
or in lieu of the foregoing as may be permitted from time to time by applicable
law.
(b) Utilize the remedy described in California Civil Code Section
1951.4 (Landlord may continue this Lease in effect after Tenant's breach and
abandonment and recover rent as it becomes due, if Tenant has the right to
sublet or assign, subject only to reasonable limitations), as follows:
(i) Landlord can continue this Lease in full force and effect
without terminating Tenant's right of possession, and Landlord shall have the
right to collect rent and other monetary charges when due and to enforce all
other obligations of Tenant hereunder. Landlord shall have the right to enter
the Premises to do acts of maintenance and preservation of the Premises, to make
alterations and repairs in order to relet the Premises, and/or to undertake
other efforts to relet the Premises. Landlord may also remove personal property
from the Premises and store the same in a public or private warehouse at
Tenant's expense and risk. No act by Landlord permitted under this paragraph
shall terminate this Lease unless a written notice of termination is given by
Landlord to Tenant or unless the termination is decreed by a court of competent
jurisdiction.
(ii) In furtherance of the remedy set forth in this Section ,
Landlord may relet the Premises or any part thereof for Tenant's account, for
such term (which may extend beyond the Lease term), at such rent, and on such
other terms and conditions as Landlord may deem advisable in its sole
discretion. Tenant shall be liable immediately to Landlord for all costs
Landlord incurs in reletting the Premises. Any rents received by Landlord from
such reletting shall be applied to the payment of: (a) first, any indebtedness
other than rent due hereunder from Tenant to Landlord; (b) second, the costs of
such reletting, including brokerage and attorney's fees and the
15
16
cost of any alterations and repairs to the Premises; and (c) third, the payment
of rent due and unpaid hereunder. Any remainder shall be held by Landlord and
applied in payment of future amounts as the same become due and payable
hereunder. In no event shall Tenant be entitled to any excess rent received by
Landlord after a breach of this Lease by Tenant and the exercise of Landlord's
remedies hereunder. If the rent from such reletting during any month is less
than the rent payable hereunder, Tenant shall pay such deficiency to Landlord
immediately upon demand.
14.2 Worth at the Time of Award. As used in Section 14.1(a)(i) and
14.1(a)(ii) above, the "worth at the time of award" shall be computed by
allowing interest at the lesser of twelve percent (12%) per annum or the maximum
rate permitted by law. As used in Section 14.1(a)(iii), above, the "worth at the
time of award" shall be computed by discounting such amount at the discount rate
of the Federal Reserve Bank of San Francisco at the time of award plus one
percentage point per annum.
14.3 Notification of Reletting. In the event Landlord terminates this
Lease pursuant to Section 14.1(a) above, and Tenant has made an advance payment
of rent as defined in California Civil Code Article 1951.7, and Tenant has
requested in writing that Landlord notify it of any initial reletting of
Premises, then and only then must Landlord notify Tenant pursuant to California
Civil Code Article 1951.7(c) that the Premises have been relet.
14.4 Right of Landlord to Re-Enter. In the event of any termination of
this Lease, Landlord shall have the immediate right to enter upon and repossess
the Premises, and any personal property of Tenant may be removed from the
Premises and stored in any public warehouse at the risk and expense of Tenant.
14.5 Landlord's Right to Pursue Other Remedies. In the event of any breach
of this Lease, Landlord may pursue any of the foregoing remedies, and Landlord
may consecutively or concurrently therewith pursue any other remedy or enforce
any right to which Landlord may be entitled by law.
14.6 Landlord's Default. Landlord's failure to perform any of its
obligations under this Lease shall constitute a default by Landlord under this
Lease if the failure continues for thirty (30) days after written notice of the
failure from Tenant to Landlord. If the required performance cannot be completed
within thirty (30) days, Landlord's failure to perform shall not constitute a
default if Landlord undertakes to cure the failure within such thirty (30) day
period and thereafter diligently pursues such cure to completion.
ARTICLE 15. SUBORDINATION
15.1 This Lease and the leasehold estate created hereby are and shall be,
at the option and upon written declaration of Landlord, subject, subordinate and
inferior to the lien and estate of any liens, trust deeds and encumbrances, and
all renewals, extensions or replacements thereof, now or hereafter imposed by
Landlord upon the Premises or any part of the Building. Landlord hereby
expressly reserves the right, at its option and declaration, to place liens,
trust deeds and encumbrances upon and against the Premises and/or any part
thereof and/or the Building, superior in lien and effect to this Lease and the
estate created hereby. The execution by Landlord and the recording in the Office
of the County Recorder of the county in which the Premises are situated, of a
declaration that this Lease and leasehold estate are subject, subordinate and
inferior to any lien, trust deed or encumbrance placed by Landlord upon or
against the Premises, and/or any part thereof and/or the Building, shall, of and
by itself (in favor of any lienor, mortgagee, beneficiary, trustee or title
insurance company insuring the interest of any such person) and without further
notice to or act or agreement of Tenant, make this Lease and the estate created
hereby subject, subordinate and inferior thereto. Notwithstanding the foregoing,
Tenant agrees, on request of Landlord, to forthwith execute and acknowledge any
reasonable subordination agreement or other documents required to establish of
record the priority of any such encumbrance over this Lease, and also to execute
and deliver to Landlord, promptly on request, any reasonable estoppel
certificate or other statement to be furnished to any prospective purchaser or
lender against the Premises stating the matters specified in Article 27 hereof.
16
17
15.2 In the event any proceedings are brought for foreclosure, or in the
event of the exercise of the power of sale under any mortgage or deed of trust
made by the Landlord covering the Premises, the Tenant shall attorn to the
purchaser upon any such foreclosure or sale and recognize such purchaser as the
Landlord under this Lease. Tenant's obligations to provide a subordination
agreement or other documents pursuant to Section 15.1 or to attorn to the
purchaser under this Section 15.2 shall be conditioned upon the lender executing
and delivering to Tenant a commercially reasonable non-disturbance agreement.
15.3 The provisions of this Article to the contrary notwithstanding, and
so long as Tenant is not in default hereunder, this Lease shall remain in full
force and effect for the full term hereof.
15.4 Landlord agrees to use reasonable best efforts to obtain and deliver
to Tenant a commercially reasonable non-disturbance agreement from any lender
with a lien on the Building senior to this Lease.
ARTICLE 16. ATTORNEY'S FEES
In case any suit shall be brought for any unlawful detainer of the
Premises, for the recovery of any Rent due under this Lease, or because of the
breach or alleged breach of any other covenant herein contained on the part of
either party to be kept or performed, the prevailing party shall recover from
the non-prevailing party all reasonable costs and expenses incurred therein,
including reasonable attorney's fees, and reasonable attorney's fees and
expenses incurred in enforcing any judgment. Further, if for any reason Landlord
consults legal counsel or otherwise incurs any costs or expenses as a result of
its rightful attempt to reasonably enforce the provisions of this Lease, even
though no litigation is commenced, or if commenced is not pursued to final
judgment, Tenant shall be obligated to pay to Landlord, in addition to all other
amounts for which Tenant is obligated hereunder, all of Landlord's reasonable
costs and expenses incurred in connection with any such acts, including
reasonable attorneys' fees.
ARTICLE 17. ASSIGNMENT AND SUBLETTING
17.1 Landlord's Consent Required. The purpose of this Lease is to transfer
possession of the Premises to Tenant for Tenant's personal use and Tenant has
not entered into this Lease for the purpose of obtaining the right to convey the
leasehold to others. The ability of Tenant to assign or sublet the Premises is
subsidiary and incidental to the underlying purpose of this Lease. Tenant will
not, either voluntarily or by operation of law, assign, transfer, mortgage,
pledge, hypothecate or encumber this Lease or any interest herein, and will not
sublet the Premises or any part thereof or any right or privilege appurtenant
thereto, or allow any other person (the employees, agents, servants and invitees
of Tenant excepted) to occupy or use the Premises or any portion thereof,
without the prior written consent of Landlord, which consent will not be
unreasonably withheld or delayed. If Tenant is a partnership or corporation, any
cumulative transfer of more than fifty percent (50%) of the partnership
interests, or fifty percent (50%) of the voting stock (unless Tenant's stock is
publicly traded on a nationally recognized exchange), as the case may be, will
be deemed to be an assignment by Tenant of this Lease which assignment requires
the prior written consent of Landlord. Tenant shall have the right without
Landlord's consent (but with prior written notice to Landlord) to enter into an
assignment or sublease with any entity controlling or controlled by Tenant or
any entity succeeding to substantially all of the assets of Tenant as a result
of a consolidation or merger, or any entity to which all or substantially all of
the assets of Tenant have been sold, provided that on or before the effective
date of any such transfer, the assignee, sublessee or transferee executes and
delivers to Landlord an assignment and assumption agreement in form and content
satisfactory to Landlord and executed by Tenant and such assignee, sublessee or
transferee, as the case may be and that the assignee, sublessee or transferee
has a net worth on the date of the assignment equal to or greater than Tenant's
net worth on the date of this Lease. Landlord's consent shall not be required
for any transfer of the stock of Tenant so long as Tenant's stock is publicly
traded on a nationally recognized exchange.
17
18
Any transfer or subletting attempted or concluded without Landlord's prior
written consent will be void and will constitute a default under this Lease.
Consent by Landlord to any transfer (including, but not limited to, an
assignment or subletting), shall be limited to the particular transfer approved
by Landlord and shall not be deemed to be Landlord's consent to any subsequent
transfer. Tenant acknowledges Landlord shall have no obligation to sublessees
and Tenant agrees to be responsible for such parties' compliance with all rules,
regulations, and other covenants.
17.2 Landlord's Election. Tenant's request for consent to any transfer,
described in Section 17.1 above must be accompanied by a written statement
setting forth the details of the proposed transfer, including the name, type of
business and financial condition (supported by financial statements) of the
prospective transferee, financial details of the proposed transfer (e.g. the
terms of the transaction, the rent and security deposit payable under any
assignment or sublease), copies of all agreements and other writings pertaining
in any way to the proposed transfer. Tenant, in addition to the foregoing
information which must be delivered to Landlord at the time Tenant requests
Landlord's consent to the proposed transfer, shall deliver to Landlord any
additional information concerning the proposed transfer or prospective
transferee as Landlord may reasonably request. Landlord will have the right (i)
to reasonably withhold consent; or (ii) to grant written consent to the
transfer. Within fifteen (15) business days after submission of all required
information for the request for consent of proposed transfer, Landlord shall
give notice to Tenant of its election under this Section . If Landlord fails to
give such notice, Landlord shall be presumed to have denied Tenant's request for
such proposed transfer.
17.3 Withholding Consent. Under Section 17.2(i), Landlord may withhold its
consent to the proposed transfer on any reasonable ground. Such reasonable
grounds shall include, without limitation, any one or more of the following:
(i) That the prospective transferee's financial condition is
or may become insufficient to support all of the financial and other obligations
of this Lease;
(ii) That the use to which the Premises will be put by the
prospective transferee is inconsistent with the terms of this Lease or other
existing leases or is otherwise not suitable for a first class office building;
(iii) That the nature of the prospective transferee's proposed
or likely use of the Premises would involve any increased risk of the use,
release or mishandling of hazardous materials;
(iv) That the prospective transferee is not likely to conduct
on the Property a business of a quality substantially equal to that conducted by
other typical businesses operating within the Scientific Research Zoning
Ordinance;
(v) That Landlord has not received assurances acceptable to
Landlord in its sole discretion that all past due amounts owing from Tenant to
Landlord (if any) will be paid and all other defaults on the part of Tenant (if
any) will be cured prior to the effectiveness of the proposed transfer.
If Landlord withholds its consent to the proposed transfer pursuant to
Section 17.2(i), and if Tenant shall so request in writing, Landlord shall
provide to Tenant a statement of the basis on which Landlord denied its consent
within a reasonable time after the receipt of Tenant's notice. Tenant
acknowledges and agrees that each of the rights of Landlord in the event of
proposed transfer set forth in this Article is a reasonable restriction on
transfer for purposes of California Civil Code Section 1951.4.
17.4 Tenant's Obligations Continuing. No transfer within the scope of this
Article, whether with or without Landlord's consent, will release Tenant or
change Tenant's primary liability to pay Rent and to perform all other
obligations of Tenant under this Lease. Landlord's acceptance of Rent from any
other person is not a waiver of any provision of this Section . If Tenant's
transferee defaults under this Lease, Landlord may proceed directly against
Tenant
18
19
without pursuing remedies against the transferee. Landlord may consent to
subsequent assignments or modifications of this Lease by Tenant's transferee,
without notifying Tenant or obtaining its consent, and such action will not
relieve Tenant of its liability under this Lease.
17.5 Excess Rental. With respect to any sublease entered into by Tenant
with Landlord's consent as herein provided, if the rent and other compensation
paid by the subtenant to Tenant under such sublease, and all agreements and
other instruments pertaining in any way thereto, exceeds the Rent being paid by
Tenant to Landlord computed on a square foot basis (i.e., the amount by which
the rent and other compensation being paid by the subtenant to Tenant exceeds
the Rent being paid by Tenant to Landlord under this Lease for each square foot
leased by such subtenant) then Landlord will be entitled to fifty percent (50%)
of such excess ("Excess Rent") and Tenant will pay to Landlord such Excess Rent
within five (5) days after receipt by Tenant of the same. If Tenant receives any
fee, bonus or other payment (whether payable in one or more installments) from
any assignee or sublessee as partial consideration for the making of such
sublease or assignment ("Bonus Payment"), fifty percent (50%) of such Bonus
Payment shall be paid over to Landlord as additional rent hereunder.
Notwithstanding the foregoing, any Excess Rent or Bonus Payment shall be
determined after deducting the amount of out-of-pocket expenses actually
incurred by Tenant for reasonable and customary brokerage commissions,
attorneys' fees, tenant improvements, monetary and non-monetary lease
concessions (including free rent) or other expenses in connection with sublease
or assignment provided Tenant delivers sufficient evidence of such expenses to
Landlord.
17.6 Security Interest. Tenant immediately and irrevocably assigns to
Landlord as security for Tenant's obligations under this Lease all rent from any
subletting of all or a part of the Premises as permitted by this Lease, and
Landlord as assignee and as attorney-in-fact for Tenant, or a receiver for
Tenant appointed on Landlord's application, may collect such rent and apply it
toward Tenant's obligations under this Lease; except that, until the occurrence
of an event of default by Tenant, Tenant will have the right to collect such
rent.
17.7 Transfer Fee. In the event Tenant requests Landlord's consent to a
sublease or assignment hereunder, Tenant shall reimburse Landlord for all
attorney's fees incurred by Landlord in connection with review and preparation
of documents in connection with such sublease or assignment and will pay
Landlord a reasonable fee, not to exceed $250, for Landlord's processing of
documents necessary to the giving of such consent and/or assumption by the
assignees.
ARTICLE 18. PARKING
Landlord shall maintain approximately 3.25 parking spaces per 1,000
rentable square feet within the Project, and Tenant shall have the right, in
connection with its use and occupancy of the Premises, to use its Pro-Rata Share
of such spaces on a non-reserved basis. Other than payments of Rent required
hereunder, Tenant shall have the right to use such parking spaces at no
additional cost. Tenant may elect to have Landlord stripe five (5) visitor
parking spaces and seven (7) car pool spaces directly in front of the north
entrance to the Building at Landlord's expense. Such striped parking spaces will
be part of Tenant's Pro-Rata Share of parking spaces.
ARTICLE 19. NOTICES
19.1 Manner of Service. All notices, demands or requests from one party to
another shall be personally delivered or sent by mail, certified or registered,
postage prepaid, to the address stated in this Article.
19.2 Notice of Landlord. All such notices, demands or requests from Tenant
to Landlord shall be given to Landlord, addressed as follows:
Professors Fund I, as Managing Agent for All Spectrum Services, Inc.
Attn.: Elizabeth J. Clarquist
6170 Cornerstone Court East, Suite 140
San Diego, CA 92121
19
20
with copy to: Luce, Forward, Hamilton & Scripps LLP
Attn.: David M. Hymer
600 West Broadway, 26th Floor
San Diego, CA 92101
Landlord may change its address for notices by giving written notice of
such change to Tenant in the manner provided by this Article 19.
19.3 Notice to Tenant. All such notices, demands or requests from Landlord
to Tenant shall be given to Tenant, addressed, if prior to the Commencement
Date, to Tenant's Notice Address and, after the Commencement Date, to the
Premises.
ARTICLE 20. HOLDING OVER BY TENANT
Tenant agrees upon the expiration or termination of this Lease,
immediately and peaceably to yield up and surrender the Premises, notice to quit
or vacate is hereby expressly waived. Tenant shall be liable to Landlord for any
and all damages incurred by Tenant as the result of any failure by Tenant,
timely, to surrender possession of the Premises as required herein. If Tenant
shall hold over after the expiration of this Lease for any cause, such holding
over shall be deemed a tenancy at sufferance or, at the sole discretion of
Landlord, a tenancy from month-to-month only, in which event such month-to-month
tenancy shall be upon the same terms, conditions and provisions as in this Lease
contained, 125% of the monthly Rent as was in effect immediately prior to the
termination.
ARTICLE 21. WAIVER
One or more waivers by Landlord of any breach of any covenant or condition
shall not be construed as a waiver of a subsequent or continuing breach of the
same or of any covenant or condition, and the consent or approval by Landlord to
any act by Tenant requiring Landlord's consent or approval shall not be deemed
to waive or render unnecessary Landlord's consent or approval to or of any
subsequent act. No waiver of any provision of this Lease shall be deemed to have
been made, unless it be in writing and signed by the party to be charged
therewith.
ARTICLE 22. LANDLORD'S RIGHT OF ENTRY
Landlord and its agents may enter upon the Premises at any time in cases
of emergency and otherwise at any reasonable time during normal business hours
after reasonable notice to Tenant and with Tenant's supervision to post such
notices as Landlord may deem necessary to exempt Landlord and Landlord's title
from responsibility on account of any work or repairs done by Tenant upon or in
connection with the Premises; to inspect and examine the Premises and see that
the covenants hereof are being kept and performed; to make such repairs,
additions or improvements as Landlord shall deem necessary; or, to exhibit the
Premises to prospective lessees or purchasers thereof provided that Landlord
shall use reasonable efforts not to unreasonably interfere with Tenant's
business operations.
ARTICLE 23. TIME OF THE ESSENCE
Time is expressly declared to be of the essence of this Lease, and of all
covenants and conditions herein contained.
ARTICLE 24. SUCCESSORS AND ASSIGNS
The covenants and conditions herein contained shall, subject to the
provisions of Article 17 and this Article, apply to and bind the heirs,
successors, executors, administrators and assigns of the respective parties
hereof. If this Lease is signed by more than one person as Tenant, their
obligation shall be joint and several.
20
21
Landlord may freely and fully assign its interest hereunder. The term
"Landlord" shall mean only the owner at the time in question of the Building or
of a lease of the Building, so that in the event of any transfer or transfers of
title to the Building or of Landlord's interest in a lease of the Building, the
transferor shall be and hereby is relieved and freed of all obligation of
Landlord under this Lease accruing after such transfer, and it shall be deemed,
without further agreement, that such transferee has assumed and agreed to
perform and observe all obligations of Landlord herein during the period it is
the holder of Landlord's interest under this Lease. Tenant shall attorn to and
recognize as its landlord under this Lease any transferee of the Building or
Landlord's interest hereunder. In any event, Tenant shall look only to
Landlord's estate and property in the Building and the land on which it is
located for satisfaction of Tenant's remedies for the collection of a judgment
(or other judicial process) requiring the payment of money by Landlord in the
event of any default by Landlord hereunder, and no other property or assets of
Landlord or its officers, directors, agents, employees, affiliates, partners or
principals, disclosed or undisclosed, shall be subject to levy, execution or
other enforcement procedure for the satisfaction of Tenant's remedies under or
with respect to this Lease, the relationship of Landlord and Tenant hereunder or
Tenant's use or occupancy of the Premises, and no such parties shall be named in
any action or suit by Tenant against Landlord.
ARTICLE 25. BUILDING NAME
Tenant shall not use the name of the Building or words to that effect in
connection with any business on the Premises without the written consent of
Landlord. Landlord may change the name of the Building at any time without
consent of or notice to Tenant.
ARTICLE 26. KEYS
Tenant may re-key the Premises at any time provided that Tenant shall
provide two (2) copies of each access card and each key to the Premises at the
time any re-keying is done.
ARTICLE 27. ESTOPPEL CERTIFICATES
Tenant agrees, at any time and from time to time, upon not less than five
(5) days prior written notice by Landlord, to execute, acknowledge and deliver
to Landlord, a statement in writing (i) certifying this Lease is unmodified and
in full force and effect, or, if there have been modifications, this Lease is in
full force and effect as modified, and stating any such modifications; (ii)
certifying that Tenant has accepted possession of the Premises, and that any
improvements required by the terms of this Lease to be made by the Landlord have
been completed to the satisfaction of the Tenant or if not the case, any
discrepancies therefrom; (iii) stating that no rent under this Lease has been
paid more than thirty (30) days in advance of its due date or if not the case,
any discrepancies therefrom; (iv) stating the address to which notices to Tenant
should be sent; (v) certifying that Tenant, as of the date of any such
certification, has no charge, lien or claim of set-off under this Lease, or
otherwise, against rents or other charges due or to become due hereunder or if
not the case, any discrepancies therefrom, and (vi) stating whether or not, to
the best of Tenant's knowledge, Landlord is in default in the performance of any
covenant, agreement or condition contained in this Lease, and, if so, specifying
each such default of which Tenant may have knowledge and (vii) stating such
other matters as Landlord may reasonably request. Any such statement delivered
pursuant hereto may be relied upon by Landlord, any owner of the Building, any
prospective purchaser of the Building, any mortgagee or prospective mortgagee of
the building or of Landlord's interest, or any prospective assignee of any such
mortgagee.
Provided Tenant has received written notice of the mailing address of any
mortgagee of Landlord, Tenant further agrees that, from the date of execution of
this Lease, it will not seek to terminate this Lease by reason of any act or
omission of the Landlord, until the Tenant shall have given written notice of
such act or omission to Landlord's mortgagee and until a reasonable period of
time shall have elapsed following the giving of such notice, during which period
of time Landlord's mortgagee shall have the right, but shall not be obligated,
to remedy such action or omission.
21
22
ARTICLE 28. FORCE MAJEURE
Landlord shall not be required to perform any of its obligations under
this Lease, nor be liable for loss or damage for failure to do so, nor shall
Tenant thereby be released from any of its obligations under this Lease, where
such failure arises from or through acts of God, strikes, lockouts, labor
difficulties, explosions, sabotage, accidents, riots, civil commotions, acts of
war, results of any warfare or warlike conditions in this or any foreign
country, fire and casualty, legal requirements, energy shortage, or causes
beyond the reasonable control of Landlord, unless such loss or damage results
solely from willful misconduct or negligence of Landlord or its employees.
Tenant shall not be required to perform any of its obligations under this Lease,
nor be liable for loss or damage for failure to do so, nor shall Landlord be
released from any of its obligations under this Lease, where such failure arises
from or through such force majeure events that are beyond the reasonable control
of Tenant, unless such loss or damage results solely from the willful misconduct
or negligence of Tenant or its employees; provided, however, that in no event
shall any such force majeure events excuse Tenant's obligations to pay any
monetary amounts due under this Lease.
ARTICLE 29. NO REPRESENTATIONS BY LANDLORD
Neither Landlord nor any agent or employee of Landlord, has made any
representations or promises, with respect to the Premises or the Building except
as herein expressly set forth, and no rights, privileges, easements or licenses
are acquired by Tenant except as herein set forth.
ARTICLE 30. BROKER
Tenant and Landlord warrant to each other that there are no other
brokerage commissions or fees payable in connection with this Lease except to
the Brokers named in Section 1.13 of this Lease, whose commission shall be paid
by Landlord. Tenant and Landlord agree to indemnify, defend and hold each other
harmless from any cost, liability and expense (including attorney's fees) which
the indemnified party may incur as the result of any breach of the warranty
contained in this Article 30.
ARTICLE 31. ANNOUNCEMENTS
[Intentionally Omitted]
ARTICLE 32. COUNTERPARTS
This Lease may be executed in two (2) or more counterparts, each of which
shall be an original, but all of which shall constitute on and the same
instrument.
ARTICLE 33. GOVERNING LAW AND VENUE
This Lease has been negotiated and entered into in the State of
California, and shall be governed by, construed and enforced in accordance with
the internal laws of the State of California applied to contracts made in
California by California domiciliaries to be wholly performed in California.
Venue for any action by any party pertaining to this Lease shall be in the
appropriate court located in San Diego County, California.
ARTICLE 34. CAPTIONS AND INTERPRETATIONS
Articles, Sections , paragraph titles or other captions contained in this
Lease are inserted as a matter of convenience and for reference and in no way
define, limit, extend or describe the scope of this Lease or any provision
hereof. No provision in this Lease is to be interpreted for or against either
party because that party or its legal representative drafted such provision.
22
23
ARTICLE 35. SEVERABILITY
If any term, covenant, condition or provision of this Lease is held by a
court of competent jurisdiction to be invalid, void or unenforceable, the
remainder of the provisions shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.
ARTICLE 36. LEASE NOT EFFECTIVE UNTIL EXECUTED
Submission by Landlord of this Lease for examination or signature by
Tenant shall not constitute adoption and this Lease shall not become effective
until executed by both Tenant and Landlord and delivery made of the fully
executed instrument to such parties. The Lease shall not be deemed to be
executed by Landlord until signed by an authorized General Partner of Landlord.
ARTICLE 37. HAZARDOUS SUBSTANCES
37.1 Hazardous Substance Restriction. Tenant shall not cause or permit any
Hazardous Substance to be used, stored, generated, or disposed of on or in the
Premises by Tenant, Tenant's agents, employees, contractors, licensees, or
invitees, except for Hazardous Substances used by Tenant in quantities typical
for similar uses and in a manner in strict compliance with all federal, state
and local laws, ordinances, rules, regulations, statutes, codes and orders
("Environmental Laws"). Tenant, at its sole cost and expense, shall comply with
all Environmental Laws relating to the receiving, handling, use, storage,
accumulation, transportation, generation, spillage, migration, discharge,
release and disposal by or on behalf of Tenant of any Hazardous Substance in,
on, under or about the Premises. If Hazardous Substances are used, stored,
generated, or disposed of on or in the Premises in violation of the foregoing
sentence, or if the Premises become contaminated in any manner due to an act or
omission of Tenant, Tenant's agents, employees, contractors, licensees or
invitees, Tenant shall indemnify, defend and hold harmless Landlord from any and
all claims, damages, fines, judgments, penalties, costs, liabilities, or losses
(including, without limitation, a decrease in value of the Premises, damages
caused by loss or restriction of rentable or usable space), or any damages
caused by adverse impact on marketing of the space, and any and all sums paid
for settlement of claims, litigation expenses, reasonable attorney's fees,
reasonable consultation, and reasonable expert fees of whatever kind or nature,
known or unknown, contingent or otherwise arising therefrom. This
indemnification includes, without limitation, any and all costs incurred because
of any investigation of the site or any cleanup, removal, or restoration
mandated by a federal, state, or local agency or political subdivision. Without
limitation of the foregoing, if Tenant caused or permits the presence of any
Hazardous Substances on the Premises and that results in contamination, Tenant
shall promptly, at its sole expense, take any and all actions necessary to
remediate any such Hazardous Substance and return the Premises to a condition
that fully complies with all Environmental Laws. Tenant shall first obtain
Landlord's approval for any such remedial action. The provisions of the
paragraph 37.1 shall be in addition to any other obligations and liabilities
Tenant may have to Landlord under this Lease or at law or equity and shall
survive the transactions contemplated herein and shall survive the termination
of this Lease.
37.2 Hazardous Substance Defined. As used in Section 37.1, "Hazardous
Substance" means any substance that is toxic, ignitable, reactive, or corrosive
and that is regulated by any local government, the State of California, or the
United States Government. "Hazardous Substance" includes any and all material or
substances that are defined as "hazardous waste", "extremely hazardous waste",
or a "hazardous substance" or similar term pursuant to state, federal, or local
governmental law now or hereafter enacted. "Hazardous Substance" includes, but
is not restricted to, asbestos, polychlorobiphenyls ("PCB's), and petroleum
products.
37.3 Landlord Indemnity. Landlord represents that, to Landlord's actual
knowledge, without duty of inquiry or investigation, except as set forth in the
Phase I environmental assessment of the Premises dated April 17, 1996, prepared
by Douglas K. Eilar and previously provided to Tenant (the "Phase I"), as of the
Commencement Date it is unaware of any Hazardous Substances present in, on, or
under the Project in violation of Environmental Laws except as disclosed by the
Phase I. Landlord agrees to indemnify, defend and hold Tenant harmless from and
against any
23
24
and all claims, damages, fines, judgments, penalties, costs, liabilities or
losses and expenses (including reasonable attorneys' fees and consultant and
expert fees) arising from or relating to Hazardous Substances present within, on
or under the Premises in violation of applicable laws prior to the Commencement
Date, excluding, however, any Hazardous Substances brought onto the Premises by
Tenant or any of its agents, employees or contractors.
ARTICLE 38. RULES AND REGULATIONS
Tenant agrees to abide by all rules and regulations of the building
imposed by Landlord as set forth in Exhibit "B" attached to the Lease, as the
same may be reasonably changed from time to time upon reasonable notice to
Tenant provided they do not conflict with this Lease. Any violation of such
Rules and Regulations which continues after written notice by Landlord shall
constitute a default by Tenant, subject to the cure period set forth in Section
14.1(ii). Landlord shall enforce the rules and regulations in a
non-discriminatory manner. Landlord shall not be liable for the failure of any
Tenant, or its servants, employees, agents, contractors, licensees or invitees
to conform to and comply with such rules and regulations.
ARTICLE 39. ENTIRE AGREEMENT
This Lease constitutes the entire agreement between the parties hereto
pertaining to the subject matter hereof, and no oral statements or
representations or prior written matter not contained or referred to herein
shall have any force or effect. This Lease fully supersedes any and all prior
understandings, representations, warranties and agreements between the parties
hereto, or any of them, pertaining to the subject matter hereof, and may be
modified only by written agreement, signed by all of the parties hereto.
ARTICLE 40. SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT
Tenant shall execute a Subordination, Non-Disturbance and Attornment
Agreement substantially in the form attached hereto as Exhibit C upon Landlord's
request.
ARTICLE 41. RIGHT OF FIRST NEGOTIATION
Provided Tenant is in occupancy and is leasing the entire Premises and
provided Tenant is not in default of the terms and conditions of this Lease,
Tenant shall have a first right of negotiation on the terms and conditions
described below on all available space within the Project, subject to any
existing renewal, expansion or similar rights of existing tenants. In the event
Landlord receives an offer to lease any said available space that Landlord
intends to accept, Landlord shall notify Tenant of such offer. If Tenant
delivers written notice of Tenant's exercise of the right of first negotiation
within two (2) business days after delivery of Landlord's notice, Landlord and
Tenant shall meet and attempt negotiate in good faith terms which are acceptable
to the parties, each in their sole and absolute discretion. If, within fifteen
(15) days after Landlord's notice of an offer to Tenant, the parties have not
entered into a lease agreement for any expansion, or Tenant does not elect to
exercise its first right of negotiation within two (2) business days after
delivery of Landlord's notice, then Landlord shall have the absolute right at
any time within six (6) months thereafter to lease such space free of any rights
of Tenant, provided that Tenant's right of first negotiation shall apply to such
space if it again becomes available at the end of such lease.
ARTICLE 42. OPTION TO RENEW
42.1 Grant of Option. Landlord hereby grants to Tenant one (1) option (the
"Option") to renew the Term for a period of two (2) years (the "Extension").
During any Extension, the terms and conditions set forth in this Lease shall
apply, except that Basic Rent for the Extension shall be adjusted to an amount
equal to the prevailing market rate on the commencement date of such Extension.
The Option shall be exercised only by written notice delivered to Landlord at
least six (6) months, but not more than twelve (12) months, before the
expiration of the initial Term of this Lease. If Tenant fails to timely deliver
written notice of exercise of any Option to Landlord, the Option shall lapse,
and Tenant shall have no further right to extend the Term of this Lease. If
24
25
Tenant so exercises the Option, then, effective on the commencement date of the
applicable Extension, all references herein to the Term of this Lease shall
include such Extension, except for references to the "initial Term."
42.2 Prevailing Market Rate. The term "prevailing market rate" shall mean
the prevailing market rate on the commencement date of the applicable Extension
(i) for leases for a comparable term to the Extension of comparable space within
the Project or (ii) if no such comparable leases have been entered into during
the prior twelve (12) months, for leases for a term equal to the term of the
Extension of comparable space within similar buildings within the City of San
Diego Scientific Research Zoning Ordinance, entered into during the preceding
twelve (12) months, in either case giving appropriate consideration to rental
rates per rentable square foot, rental escalations, rental abatements, tenant
improvement allowances and other terms that would directly affect the economic
terms of a Lease. Landlord and Tenant shall commence negotiation of the
prevailing market rate within fifteen (15) days after Tenant delivers a written
notice to Landlord of its exercise of an Option. If Landlord and Tenant do not
agree, after good faith negotiations, within twenty (20) days, then each party
shall submit to the other a proposal containing the prevailing market rate the
submitting party believes to be correct ("Extension Proposal"). If either party
fails to timely submit an Extension Proposal, the other party's submitted
proposal shall determine the Basic Rent for the Extension.
42.3 Determination. If both parties submit Extension Proposals, then
Landlord and Tenant shall meet within seven (7) days after delivery of the last
Extension Proposal and make a good faith attempt to mutually appoint a certified
MAI real estate appraiser who shall have been active full-time over the previous
ten (10) years in the appraisal of comparable properties located in the San
Diego area. If Landlord and Tenant are unable to agree upon a single appraiser,
then each shall, within ten (10) days after the meeting, select an appraiser
that meets the foregoing qualifications. The two (2) appraisers so appointed
shall, within five (5) days after their appointment, appoint a third appraiser
meeting the foregoing qualifications. The determination of the appraiser(s)
shall be limited solely to the issue of whether Landlord's or Tenant's Extension
Proposal most closely approximates the prevailing market rate. The decision of
the single appropriate or of the appraiser(s) shall be made within thirty (30)
days after the appointment of a single appraiser or the third appraiser, as
applicable. The appraiser(s) shall have no authority to create an independent
structure of prevailing market rate or prescribe or change any or several of the
components or the structure of the prevailing market rate; the sole decision to
be made shall be which of the parties' Extension Proposals shall determine the
prevailing market rate for the Extension. The decision of the single appraiser
or majority of the three (3) appraisers shall be binding upon the parties. If
either party fails to appoint an appraiser within the time period specified
above, the appraiser appointed by one of them shall reach a decision which shall
be binding upon Landlord and Tenant. The cost of the appraisals shall be paid
equally by Landlord and Tenant. If the prevailing market rate is not determined
by the first day of the Extension, then Tenant shall pay Landlord Basic Rent in
an amount equal to the Basic Rent in effect immediately prior to the Extension
until such determination is made. After the determination of the prevailing
market rate, the parties shall make any necessary adjustments to such payments
made by Tenant.
42.4 Conditions to Exercise. Tenant's exercise of the Renewal Option(s)
shall be subject to the express conditions that (i) at the time of exercise, and
through the commencement of the Extension, Tenant shall not be in default
hereunder beyond any applicable notice and cure period and (ii) Tenant has not
been ten (10) or more days late in the payment of rent more than a total of
three (3) times during the term of this Lease. The Option is personal to Tenant
and cannot be transferred without Landlord's consent in accordance with this
Lease except to an assignee pursuant to an assignment that does not require
Landlord's consent under this Lease. In addition, Tenant may not exercise the
Renewal Option(s) unless it then occupies at least fifty percent (50%) of the
Premises.
ARTICLE 43. QUIET ENJOYMENT
Provided Tenant has performed all of the terms, covenants, agreements and
conditions of this Lease, including the payment of Rent, to be performed by
Tenant, Tenant shall peaceably and
25
26
quietly hold and enjoy the Premises for the term hereof, without hindrance from
Landlord or any party claiming under or through Landlord, subject to the terms
and conditions of this Lease.
LANDLORD:
PROFESSORS FUND I, L.P., AN ARIZONA LIMITED
PARTNERSHIP, MANAGING AGENT FOR ALL
SPECTRUM SERVICES, INC., A CALIFORNIA
CORPORATION
BY: /S/ ELIZABETH J. CLARQUIST
-----------------------------------------
ELIZABETH J. CLARQUIST, GENERAL PARTNER
TENANT:
IDEC PHARMACEUTICALS CORPORATION,
A CALIFORNIA CORPORATION
BY: /S/ PHILLIP M. SCHNEIDER
-----------------------------------------
TITLE: VICE PRESIDENT
--------------------------------------
26
27
EXHIBIT A
PREMISES FLOOR PLAN
27
28
EXHIBIT A-1
Legal Description of Real Property
Parcel A:
Parcel 1 of Parcel Map No. 12041, in the City of San Diego, County of San
Diego, State of California, filed in the Office of the County Recorder of San
Diego County, April 2, 1982 as File No. 82-090385, of Official Records.
Parcel B:
An easement and right of way for ingress and egress, road and utility purposes,
including but not limited to electric power, telephone, gas, water, sewer and
cable television lines and appurtenances thereto, over, under, along and across
those certain strips of land being 30.00 feet and 40.00 feet in width, the
center line of said strips being described as follows:
Commencing at the Northeasterly corner of Parcel 2 of Parcel Map No. 12041, in
the county of San Diego, State of California, filed in the Office of the County
Recorder of San Diego, April 2, 1982 as File No. 82-090385, of Official
Records; thence South 64 (degrees) 19 (feet) 32 (inches) West 158.61 feet to
the True Point of Beginning of said 30.00 foot strip; thence continuing South
64 (degrees) 19 (feet) 32 (inches) West 25.00 feet; thence South 14 (degrees)
42 (feet) 19 (inches) West 248.58 feet, to a point being the termination of
said 30.00 foot strip, said point also being the beginning of said 40.00 foot
strip; thence South 19 (degrees) 02 (feet) 41 (inches) East 393.00 feet to a
point in the South line of said Parcel Map No. 12041, said point also being the
point of termination.
EXCEPTING THEREFROM that portion lying within Parcel A above.
28
29
EXHIBIT B
RULES AND REGULATIONS
Any violation of these rules and regulations, which continues after
written notice by Landlord, shall constitute a default by Tenant, subject to the
cure period set forth in Section 14.1(ii) of the Lease.
Landlord may upon request by Tenant, waive the compliance by Tenant with
any of the following rules and regulations, providing that (i) no waiver shall
be effective unless signed by Landlord or Landlord's authorized agent, (ii) any
such waiver shall not relieve Tenant from the obligation to comply with such
rule or regulation in the future unless expressly consented to, in writing, by
Landlord, and (iii) no waiver granted to any other tenant shall relieve Tenant
from the obligation of complying with the following rules and regulations unless
Tenant has received a similar waiver in writing from Landlord.
1. Landlord shall have the right to control and operate the public
portions of the Building, and the facilities furnished for the
common use of the tenants, in such manner as Landlord deems best for
the benefit of the tenants generally. Tenant shall not permit the
visit to the Premises of persons in such numbers or under such
conditions as to interfere with the use and enjoyment by other
tenants of the entrances, corridors, elevators and other public
portions or facilities of the Building.
2. The directory board at the entrance to the Building is provided for
the exclusive display of the name and location in the Building of
each tenant, and Landlord reserves the right to exclude any other
name therefrom, and to make a charge for each and every name in
addition to the name of Tenant, placed on the directory board at the
request of Tenant.
3. The water and janitor closets and other plumbing fixtures shall not
be used for any purpose other than those for which they were
constructed, and no sweepings, rubbish, rags, or other substances
shall be thrown therein. All damages resulting from any misuse of
the fixtures by Tenant or its servants, employees, agents, visitors
or licensees shall be borne by Tenant.
4. Tenant shall see that the doors of the Premises are closed and
securely locked before leaving the Premises, and must observe strict
care and caution that all water faucets or water apparatus are shut
off before Tenant or Tenant's employees leave and that all
electricity shall likewise be carefully shut off, so as to prevent
waste or damage, and for any default or carelessness Tenant shall
make good all injuries sustained by other tenants or occupants of
the Building or Landlord.
6. Tenant shall not install or use any machinery in the Premises which
may cause any unreasonable noise, jar or tremor to the floors or
walls, or which by its weight might injure the floors of the
Building. Landlord may restrict the weight, size and position of all
files, safes and heavy equipment used in the Building, and may
require such items to be mounted on a wood or metal base acceptable
to Landlord. All damage to the Building caused by installing or
removing any safe, furniture, equipment or other property shall be
repaired at the expense of Tenant.
11. Landlord reserves the right to exclude from the Building any person
who, in the judgment of the Landlord, is intoxicated or under the
influence of liquor or drugs or who is not known or does not
property identify himself to the Building management or watchman on
duty. landlord may, at its option, require all persons admitted to
or leaving the Building during secured hours to register with
Building security guards. Each tenant shall be responsible for all
persons for whom he authorizes entry into the Building, and shall be
liable to Landlord for all acts of such persons.
29
30
12. Canvassing, soliciting or peddling in the Building is prohibited and
Tenant shall cooperate to prevent same.
13. Landlord shall have the right to prohibit any advertising by Tenant
which in Landlord's opinion tends to impair the reputation of the
Building or its desirability as a Building for offices, and upon
written notice from Landlord, Tenant shall refrain from or
discontinue such advertising.
14. Tenant shall not install blinds, shades, awnings or other form of
inside or outside window coverings, or window ventilators or similar
devices without the prior written consent of Landlord.
15. Tenant shall give Landlord prompt notice of any accidents to or
defects in the water pipes, gas pipes, electric lights and fixtures,
heating apparatus or any other service equipment in the Premises or
Building.
19. The smoking of cigarettes or use of cigarettes or use of tobacco
products in any form whatsoever is prohibited with the confines of
the Premises.
20. Landlord reserves the right, from time to time, to make amendments
to the foregoing rules and regulations by giving notice to Tenant
provided such amendments do not conflict with the Lease.
LANDLORD:
PROFESSORS FUND I, L.P., AN ARIZONA LIMITED
PARTNERSHIP, MANAGING AGENT FOR ALL
SPECTRUM SERVICES, INC., A CALIFORNIA
CORPORATION
BY: /S/ ELIZABETH J. CLARQUIST
-----------------------------------------
ELIZABETH J. CLARQUIST, GENERAL PARTNER
TENANT:
IDEC PHARMACEUTICALS, CORPORATION,
A CALIFORNIA CORPORATION
BY: /S/ PHILLIP M. SCHNEIDER
-----------------------------------------
TITLE: VICE PRESIDENT
---------------------------------------
30
5
1,000
9-MOS
DEC-31-1996
JAN-01-1996
JUN-30-1996
53,105
22,971
3,611
0
1,729
84,360
25,803
7,882
103,294
9,052
0
0
26,586
142,426
(82,558)
103,294
1,505
19,907
1,384
1,134
19,011
0
354
0
0
0
0
0
0
(6,147)
(0.38)
0
